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Platelets are small and anucleate blood cells that are well known for their role in
hemostasis. Other less recognized platelet functions include contributions to cancer
vascularization, growth, and metastasis. Although the participation of platelets in cancer
biology has been broadly studied in mouse models, there is no information in the
literature regarding the crosstalk of platelets and cancer cells in dogs. The objective of
this dissertation was to explore the interaction of canine platelets and tumor cells in vitro.
The main hypothesis was that canine platelets were similar to human and murine
platelets, and would interact with tumor cells, resulting in a change in the behavior of
these cells. Using confocal immunofluorescence, we show that fibrinogen and von
Willebrand factor have little colocalization within platelets, providing evidence that
canine platelets have selective packaging and different alpha-granule subtypes, as shown
in mice and humans. Then, we demonstrate canine platelet activation by osteosarcoma
and mammary carcinoma cells, utilizing platelet aggregometry. Next, we show that intact
platelets, platelet lysate, and thrombin-activated platelet releasate have an inhibitory
effect on the migration of canine osteosarcoma and mammary carcinoma cell lines,

contrary to what is described in humans and mice. We also demonstrate that releasate
from canine platelets activated by collagen induces cancer cell migration, the opposite of
the effect of releasates derived from thrombin or adenosine diphosphate activation.
Lastly, we show that platelets can downregulate epithelial-to-mesenchymal-related
transcription factors in canine cancer cells, suggesting that platelets may play an
important role regulating this process in canine cancer progression. In conclusion, the
results of this study have revealed important interactions between canine cancer cell lines
and platelets in vitro. Our findings suggest that platelets most likely have a significant
role in cancer growth in dogs and that cancer cells most likely affect platelet function in
cancer patients.
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INTRODUCTION AND LITERATURE REVIEW

1.1

Introduction
Platelets are small and anucleated blood cells that have a variety of functions in

the body. Their classical role in primary hemostasis and vessel healing support is as
significant as their more recently discovered roles in inflammation, cancer biology, and
angiogenesis (Italiano & Battinelli, 2009). Platelets support cancer vascularization,
growth, and metastasis. The crosstalk between cancer cells and platelets is complex and,
although it has been recently intensely studied, it is still not well understood.
Cancer is a major public health problem worldwide. It is currently the second
leading cause of death in the United States and is expected to surpass heart disease as the
leading cause of death in the next few years (Siegel et al., 2015). Also in veterinary
medicine, cancer is a significant concern in both domestic pet animals and in herd health
(Kusewitt, 2012).
In vivo, cancer cells will certainly encounter platelets once they enter the
circulation, where they are shown to protect tumor cells from destruction (Palumbo et al.,
2005). However, it is also proposed that platelets are in close contact with the primary
tumor site since blood vessels in cancerous tissue are leaky, unstable and frequently
bleeding. This interaction of platelets and cancer cells in the primary mass is thought to
be crucial for the support of cancer cell migration and extravasation (Buergy et al., 2012).
1

Although the participation of platelets in cancer biology has been broadly studied
in mouse models, there is no information in the literature regarding the crosstalk of
platelets and tumor cells in dogs. Thus, the objective of this dissertation is to explore the
interaction of canine platelets and tumor cells in vitro. The understanding of this
interaction may identify features specific to metastatic tumors, and aid in the
development of more efficient and targeted anti-metastatic therapies. Another
contribution is to benefit the establishment of dogs as a suitable model of human disease
for use in clinical trials that evaluate both the diagnostic relevance of platelet-derived
cancer biomarkers and the efficacy of novel platelet modulatory cancer therapies.
As background information, the next section of this chapter contains a pertinent
literature review, which includes an overview of tumor development and platelet biology,
as well as a description of the current literature that pertains to the discussion of the in
vitro or in vivo relationship between cancer and platelets.
1.2
1.2.1

Literature review
Oncogenesis
A neoplasm is a "new growth" composed of cells originated from normal tissues

that expand beyond their normal anatomic boundaries. This growth results from genetic
alterations that are passed down to the progeny of these neoplastic cells, and allow
excessive and unregulated proliferation. Although the terms neoplasm and tumor may
refer to benign or malignant growths, the term cancer always denotes a malignant
growth. Neoplastic cells escape normal limits on cell division, become independent of
external growth stimulatory and inhibitory factors, and lose their susceptibility to
apoptotic signals (Kusewitt, 2012; Stricker & Kumar, 2010).
2

A tumor is denoted as benign when its microscopic and gross characteristics are
considered relatively innocent, implying that it will remain localized and cannot spread to
other sites. A malignant neoplasm implies that the lesion can invade and destroy adjacent
structures or that the neoplastic cell can spread to distant sites (metastasize) (Stricker &
Kumar, 2010).
The abnormalities that result in a neoplasm are multiple genetic and epigenetic
changes that accumulate over a relatively long time course, in a multistep process. The
first step is called initiation, the introduction of irreversible genetic change by the action
of an agent or initiator that damages DNA. The second stage of tumor development is
promotion, the outgrowth of initiated cells in response to selective stimuli. The final stage
is progression, which includes the conversion of a benign tumor to an increasingly
malignant tumor and/or to a metastatic tumor. Malignant conversion represents an
irreversible change in the nature of the developing tumor. Progression is a complex and
poorly understood process involving both genetic and epigenetic changes in tumor cells
and their environment that select for increasingly malignant clones of tumor cells.
Karyotypic instability in tumor cells and increasing tumor heterogeneity are hallmarks of
progression (Kusewitt, 2012).
The genetic change introduced in the initiation step can be a mutation resulting
from various agents (carcinogens) such as viruses, mutagenic chemicals, and radiation.
The genetic alteration can also be introduced by epigenetics, modifications to
chromosomes that alter gene expression patterns such as DNA methylation; and
methylation, acetylation, or phosphorylation of histones and other proteins that form
chromatin (Novak, 2004).
3

The modification of genetic material is random, and many changes may be
inconsequential. However, when nonlethal mutations occur in a small subset of the
genome, neoplasia can develop. This subset of critical genes can be divided into two
subclasses, oncogenes and tumor suppressor genes, based on their functional features
(Cullen et al., 2002). The normal cellular counterparts of the oncogenes are termed protooncogenes, and they encode proteins that participate in one or more signal transduction
pathways. Such signaling pathways regulate cell proliferation and maturation (Druker et
al., 1989), and have been conserved throughout evolution, varying little from yeast to
humans. Oncogenes can be grouped into five categories based on the types of
oncoproteins they encode. These categories include growth factors, growth factor
receptors, intracellular signal transducers, nuclear regulatory proteins (transcription
factors), and cyclins. Proto-oncogenes are converted into oncogenes by alteration of gene
expression or alteration of gene structure. Gene expression can be altered via gene
amplification, promoter insertion, and/or gene translocation. Structural alterations can
occur by mutation of individual nucleotides or alterations that may occur during more
global genetic events, such as the translocation of chromosomes. Damage to individual
nucleotides is the most common structural change sustained by proto-oncogenes (Cullen
et al., 2002).
The other group of genes involved in neoplastic transformation is tumor
suppressor genes, which play a critical role in the control of normal cell growth, serving
as "brakes" to cell replication. When tumor suppressor genes are inactivated, cells lose
regulatory control of cell proliferation. A single intact copy of a tumor suppressor gene is
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sufficient to maintain control of cell proliferation. When both alleles are lost or damaged,
the affected cell has a high risk of neoplastic transformation (Cullen et al., 2002).
1.2.2

Cancer development and spread
Cancer growth starts with a single cell that has undergone a neoplastic

transformation, and the tumor develops by clonal expansion of this one cell. Since this
clonal cell population lacks regulation of chromosomal integrity, the tumor cells acquire
genetic changes that give rise to tumor heterogeneity. Some genetic changes in these new
mutated cells are lethal, but some changes confer new phenotypes that may have inherent
growth advantages. As neoplastic cell replicates, subclones emerge that are more locally
aggressive, more likely to metastasize, and less responsive to therapy (Cullen et al.,
2002).
Metastasis, which is the growth of cancer cells at a site distant from the original
parent tumor, is the single most reliable hallmark of malignancy and is responsible for
90% of the deaths from cancer in humans. Cells may metastasize by seeding the body
cavities and surfaces (transcoelomic spread), by lymphatic spread, or by hematogenous
spread. The site at which tumor cells exit the blood vasculature or lymphatic system is
determined both by the pattern of lymphatic or vascular drainage of the primary tumor
and by the ability of tumor cells to interact with adhesion molecules on endothelial cells.
In addition, metastatic sites must provide a suitable microenvironment for tumor cell
growth (Kusewitt, 2012).
Metastasis is triggered by a multitude of tumor-host cell interactions and complex
signaling pathways in the cancer cells (Niinaka et al., 2010; G. Yang et al., 2013). Tumor
cell motility, invasion, and dissemination out of the primary tumor microenvironment are
5

mandatory steps to cause cancer metastasis (Wirtz et al., 2011). The cancer cells proceed
through several steps to successfully metastasize. After cellular transformation and tumor
growth, the tumor has to stimulate angiogenesis. Tumor cells also have to detach from the
original mass and locally invade the host stroma. Cells will then enter the bloodstream
and are transported by the circulatory system. At the metastatic site, they arrest in the
capillaries, extravasate, and proliferate within the foreign tissue (Fidler, 2003). However,
even if tumor cells successfully get into the circulation, the vast majority of circulating
cancer cells are rapidly destroyed by shear stress, which is the mechanical force exerted
by blood flow in the vasculature, or they are attacked by the immune system, and less
than 0.01% of these cells survive to produce metastases (Fidler, 1970). Tumor cell
extravasation can occur as a result of multiple mechanisms that result in cells passing
through the vessel wall and reaching the subendothelial parenchyma. The invading cells
will then establish reciprocal signaling networks with stromal cells and endothelial cells
to promote the growth of the tumor mass and angiogenesis at the seeding site (Langley &
Fidler, 2011).
Migration is a crucial process in several steps of metastasis. To acquire mobility,
a phenotype change, mainly studied in epithelial tumor cells, confers to the cells a
mesenchymal-like characteristic, which allows them to move while maintaining loose
cell-cell contacts (Thiery, 2002; Thiery et al., 2009). This process is called epithelial to
mesenchymal transition (EMT), and it plays a critical role in cancer metastasis
(Gunasinghe et al., 2012; Yao et al., 2011). EMT confers migratory and invasive abilities
to the cancer cell mainly by a coordinated process involving downregulation of the
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adherent junction protein E-cadherin and upregulation of N-cadherin (G. Yang et al.,
2013).
In epithelial tumor cells, the loss in E-cadherin and upregulation of N-cadherin,
concomitant with the acquirement of a more metastatic potential, suggests that Ncadherin expression promotes mobility in the cells. This change is accompanied by
activation of signaling pathways upregulating and activating transcription factors
including Snail1, Snail, Twist1, Twist2, zinc finger E-box-binding homeobox (ZEB)1,
and ZEB2 (Gonzalez & Medici, 2014; Thiery et al., 2009). On mesenchymal cells,
though, previous studies suggested that N-cadherin and cadherin-11 function as tumor
suppressor genes, decreasing osteosarcoma migration and metastasis. Highly metastatic
human and murine osteosarcomas express low transcriptional and post-transcriptional
levels of E-cadherin, N-cadherin, P-cadherin, and cadherin-11, suggesting that this
anomalous cadherin expression in highly malignant mesenchymal tumors is associated
with metastasis. (Kashima et al., 1999; Kashima et al., 2003).
1.2.3

Cancer angiogenesis
Angiogenesis is a complex process involving recruitment of endothelial cells from

preexisting blood vessels, endothelial cell proliferation, directed migration of endothelial
cells through the extracellular matrix (ECM), and maturation and differentiation of the
capillary sprout. This process is controlled by the balance between angiogenesisstimulating and angiogenesis-inhibiting factors (Kusewitt, 2012). Tumor cells that secrete
growth factors or stimulate other cells to release angiogenic factors stimulate the vessels
and supporting stroma in tumors. Vascular endothelial growth factor (VEGF) and acidic
and basic fibroblast growth factors (FGF) are among the most potent angiogenic factors
7

produced by tumors (Folkman, 1995; Kusewitt, 2012). Tumors lacking the ability to
stimulate vascular ingrowth are limited to a diameter of 1-2 mm (Folkman, 1995). Tumor
angiogenesis also plays an essential role in sustained tumor growth, as well as metastasis
(Pluda, 1997). The density of the microvasculature within a tumor has been shown to be a
significant prognostic indicator for some human and canine neoplasms (Moschetta et al.,
2015; Weidner et al., 1993; Weidner et al., 1991; Zizzo et al., 2010).
Interestingly, the tumor blood vessels that develop in response to angiogenic
signals are usually more dilated, more tortuous, and more permeable than normal blood
vessels (Kusewitt, 2012). There is increased interstitial pressure due to the permeable
vessels and the lack of lymphatics to carry away the leaked fluids, and this leads to
edema formation. The density of the vascular supply to tumors is frequently minimally
adequate, and the vasculature is deficient in arteriolar supply (Tannock & Rotin, 1989).
Regardless of these imperfect vessels, cancer blood supply has a powerful effect on
tumor growth and is an area of particular interest in tumor biology. For decades,
inhibition of angiogenesis has been studied as a potential cancer treatment option. After a
groundbreaking publication in the late 90’s that reported the tumor inhibitory effects of
endostatin in mouse carcinoma, fibrosarcoma, and melanoma (Boehm et al., 1997), much
effort was put into researching antiangiogenic molecules as treatment options in cancer.
Then in 2004, the first antiangiogenic therapy was approved, a monoclonal antibody
against VEGF for breast cancer treatment. Since then, several anti-angiogenic inhibitors
have been developed And used in clinical trials, and many have been approved for use in
the treatment of multiple cancers, alone or in combination with other drugs (Al-Husein et
al., 2012).
8

1.2.4

Overview of platelet function
In hemostasis, the major function of platelets is the formation of a platelet plug at

the site of vessel injury, which alone is sufficient to stop bleeding from an injury to a
small vessel. Platelets also provide a binding site for coagulation factors, by movement of
negatively charged phospholipids (primarily phosphatidylserine) from the inner surface
to the outer surface, aiding secondary hemostasis (Jurk & Kehrel, 2005). Moreover,
platelets participate in promoting coagulation by secreting platelet factor 4 (PF4/CXCL4)
during activation. This chemokine binds to heparin-like molecules on endothelial
surfaces, and displaces antithrombin (also called antithrombin III), inhibiting local
antithrombin activity (Arepally & Ortel, 2010). Finally, platelets are shown to help
maintain normal vascular integrity. Thrombocytopenic animals have thin, fragile, and
leaky endothelial vessels (Kitchens & Weiss, 1975). Several vasoactive molecules
released by platelets might participate in the maintenance of the integrity of the
endothelial barrier. Platelet-derived sphingosine-1 phosphate, for example, was shown to
be an important mediator protecting the vascular barrier (Schaphorst et al., 2003).
Besides their classical roles in hemostasis, platelets also have a variety of other
less well-known physiologic functions. These functions include participation in the innate
immune defense and modulation of the inflammatory response (Jurk & Kehrel, 2005).
Human platelets have been shown to internalize viruses and bacteria, which is believed to
happen in a selective and active fashion (Youssefian et al., 2002). Also, platelets secrete
growth factors that help wound healing. Because of this property, autologous platelet-rich
plasma (PRP) has long been used to accelerate healing processes (N. K. Jain & Gulati,
2016). Although definitive clinical evidence of its efficacy is lacking in veterinary
9

medicine, PRP has been demonstrated in experimental studies to exert beneficial effects
in the healing of tendons, ligaments and cartilage in both humans and animals (Brossi et
al., 2015). Finally, platelets play important roles in cancer biology. Platelets are known to
participate in cancer angiogenesis, aid in tumor growth, and facilitate cancer migration
and metastasis.
In the next sections of this review, platelet production, structure, and activation
will be described. Subsequently, the most up to date information on platelet function
related to their role in cancer development will be discussed.
1.2.5

Thrombopoiesis
Platelets are derived from cytoplasmic fragmentation of megakaryocytes. Mature

megakaryocytes are polyploid cells, and DNA content or ploidy correlates with the
number of platelets a megakaryocyte will ultimately produce (Stockham & Scott, 2008).
The liver is the primary site for megakaryopoiesis during human fetal
development; however, the bone marrow becomes increasingly important in the postnatal
period and ultimately becomes the major site for megakaryopoiesis in the adult (Sungaran
et al., 1997). Also, there is evidence that supports the presence of megakaryocyte and
platelet production in human and mouse lung vasculature (Levine et al., 1993; ZuckerFranklin & Philipp, 2000)
There are several differences among species regarding megakaryocyte and
platelet number and size. Mouse megakaryocytes are smaller and more numerous than in
humans. The modal ploidy value for both species is 16N. In dogs and rabbits, this number
is 32N, and in cats, the modal value is evenly split between 32N and 64N (Ebbe &
Boudreaux, 1998). In cattle, the modal ploidy varies from 64N in newborn calves to 32N
10

in adult animals (Topp et al., 1990). Platelet mass varies within species and is not always
related to megakaryocyte ploidy. Mean platelet mass ranges from 1.8 x 106 to 2.5 x 106
fL / uL in cows, dogs, goats, and cats. In mice platelet mass is 5.2 x 106 fL/µL, while in
horses platelet mass is 0.72 x 106 fL/µL (Boudreaux & Ebbe, 1998).
Terminal megakaryocyte differentiation occurs after endomitosis is completed,
and is associated with tubular invagination of the plasma membrane resulting in the
formation of the demarcation membrane system (DMS), which provides a membrane
reservoir for the formation and extension of proplatelets (Schulze et al., 2006). Synthesis
of platelet granules occurs simultaneously with the formation of the DMS, and granules
are packaged and mobilized as microtubule assembly occurs in the proplatelet extensions.
Once organelles and granules enter the proplatelet tip, they are captured there for
packaging within the developing platelet (Richardson et al., 2005). Also, besides
organelle trafficking, the evidence demonstrates that megakaryocytes provide the
developing platelets with requisite translational machinery, specifically sorting
ribosomes, initiation and termination factors, microRNAs (miRNAs), and template
messenger RNAs (mRNAs) (Rowley et al., 2012).
Proplatelets are formed in a spiraling manner starting at the periphery and moving
centripetally towards the nucleus, and they consist of long beaded strands that fragment
in circulation when subjected to shear. Shear stress within bone marrow sinusoids
probably assists in fragmentation of proplatelets from megakaryocyte bodies after
proplatelets are extended through the subendothelium (Junt et al., 2007). Proplatelet
formation consumes the entire megakaryocyte cytoplasm, leaving behind only the
nucleus, which enters an apoptotic pathway (Boudreaux, 2010b).
11

Platelet shedding from the proplatelet is assisted by microtubules, which are
hollow polymers formed by α/β-tubulin dimers. β1-tubulin is the most abundant platelet
β-tubulin isoform. The absence of this tubulin in null mice results in thrombocytopenia
and reduced numbers of marginal microtubule bands in platelets. In dogs, a missense
mutation in the β1-tubulin gene causes macrothrombocytopenia in Cavalier King Charles
Spaniels (Boudreaux, 2010b).
Megakaryopoiesis and thrombopoiesis are regulated mainly by thrombopoietin
(TPO) via signaling through its receptor, Mpl (Kaushansky, 1995). TPO also stimulates
megakaryocytes to increase in cell size and ploidy and triggers the formation of
proplatelet processes (Kaushansky, 2005b). Furthermore, TPO regulates hematopoietic
stem cell expansion and maintenance of adult quiescent cells (H. Qian et al., 2007). In
health, TPO is produced constantly and is cleared by receptor-mediated uptake and
destruction by platelets and megakaryocytes (C. Yang et al., 1999; Zent et al., 1999).
Therefore, platelet and megakaryocyte mass exerts control over plasma TPO, and there is
generally an inverse relationship between platelet concentration and blood and bone
marrow TPO concentration. However, certain pathological states can induce TPO
production (Kaushansky, 2005a).
Although the liver is the major source of TPO mRNA production throughout life
(Sungaran et al., 1997), it also found in several human, mouse and rat tissues in addition
to the liver, such as the kidney, bone marrow, lung, spleen, and central nervous system
(Dame et al., 2003; Kazama et al., 2011; McCarty et al., 1995; S. Qian et al., 1998;
Sungaran et al., 1997).

12

There is very little information regarding tissue TPO expression in dogs. A study
by our research group analyzed TPO mRNA levels in several canine tissues by
quantitative reverse transcriptase polymerase chain reaction (Figueiredo et al., 2013). The
liver had the highest level of TPO mRNA, suggesting that this tissue is also the major site
of TPO production in the dog. Remarkably, the bone marrow also had a high expression
of TPO mRNA, in contrast with the kidney, which had the lowest mRNA levels. These
findings are in contrast with what was reported in humans, mice, and rats, which all have
important or major production of TPO in renal tissue (McCarty et al., 1995; Stoffel et al.,
1996; Sungaran et al., 1997).
TPO binding to its receptor c-Mpl results in activation of Janus kinases and signal
transducers and activators of transcription (STAT) factors STAT3 and STAT5. JAK2 is
bound constitutively to c-Mpl and, upon activation, phosphorylates tyrosine residues
within c-Mpl and within STATs, PI3K, and mitogen-activated protein kinases (MAPKs).
STAT3 and STAT5 are required for regulation of normal megakaryopoiesis and have
been found to be dysregulated in some myeloproliferative disorders and in
megakaryoblastic leukemias in humans (Boudreaux, 2010b).
1.2.6

Platelet structure
Despite their simple appearance on the peripheral blood smear, platelets have a

complex ultrastructure that can be divided into four zones. The outermost zone is the
peripheral zone, and includes surface membrane phospholipids and receptors, and closely
associated structures such as the walls of the open canalicular system. The matrix of the
platelet interior is the sol-gel zone, containing actin microfilaments, structural filaments,
the circumferential band of microtubules, and glycogen. The organelle zone is embedded
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in the sol-gel zone and includes dense granules, alpha granules, lysosomes, and
mitochondria. Platelet granules and lysosomes will be discussed in more detail in
subsequent sections. The membrane zone includes the open canalicular system and the
dense tubular system (Hartwig, 2006; Sharathkumar & Shapiro, 2008; Stockham & Scott,
2008).
Similar to other cell membranes, platelet membranes are phospholipid bilayers.
However, the platelet surface membranes also contain densely compacted microdomain
lipid rafts scattered within the fluid lipid matrix. These rafts are primarily composed of
sphingolipid and cholesterol molecules, and are capable of lateral mobility and enhancing
signaling in the initial phases of platelet activation. They also participate in cytoskeletal
reorganization events critical for normal clot retraction (Bodin et al., 2005). Proteins and
glycoproteins are present both within and outside the lipid rafts. Glycoprotein (GP) IbIX-V and GPVI are examples of proteins primarily located within lipid rafts.
Glycoprotein complex IIb-IIIa is the most prevalent glycoprotein complex on the surface
of platelets and is located outside of lipid rafts (Dorahy et al., 1996).
Phospholipids within the platelet membrane are an important component of
coagulation, as they provide the surface upon which coagulation proteins react. They also
serve as the initial substrate for platelet enzymatic reactions to produce thromboxane A2
(TXA2), an important product of platelet activation and a platelet agonist (Sharathkumar
& Shapiro, 2008).
The sol-gel zone comprises the cytoskeleton that forms the support for the
maintenance of the platelet’s discoid shape as well as the contractile system that allows
shape change, pseudopod extension, internal contraction, and release of granular
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constituents (Sharathkumar & Shapiro, 2008). As a component of the cytoskeleton,
microtubules are just beneath the peripheral zone. They are hollow, cylindrical structures
composed of protofilaments formed by alpha-beta tubulin dimers arranged in a helical
head-to-tail fashion (Italiano et al., 2003). Also constituting the cytoskeleton are actin,
spectrin, adducin, filamin, and GPIb-IX-V (the von Willebrand factor receptor). The
cytoskeleton interacts with an extensive cytoplasmic actin network. Adducin links the
ends of cytoplasmic actin filaments to membrane-associated spectrin strands. Filamin
subunits bind to actin and to the cytoplasmic tails of the GPIba subunits, resulting in a
strengthening of the interaction of the spectrin/actin network with the plasma membrane
(Hartwig, 2006).
In the membrane zone is an extremely tortuous maze of open interconnecting
channels called the open canalicular system (OCS) (White & Escolar, 1991). The OCS
can act as a conduit for the uptake of particles and for the release of granule contents by
activated platelets. Particles such as viruses or bacteria can be taken up by the OCS,
which usually results in platelet activation. Alpha granules and lysosomes have been
documented to fuse and evacuate their contents into the OCS around engulfed bacteria or
viruses, but communication with the outside is always maintained, unlike the phagocytic
vacuoles of leukocytes. Thus, platelets are not considered to be true phagocytes (Berger
et al., 1996). The OCS is reverted to some extent during platelet activation, and can thus
serve to increase the number of surface receptors available for ligand binding since many
of the same receptors found on the platelet surface also line the OCS. Unlike in humans,
dogs, and cats, ruminant and equine platelets do not possess a developed OCS (Gader et
al., 2008). Platelets from these species do not enhance their surface area during
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activation, do not have a mechanism for uptake of particles, and release their granule
contents by fusion of granules directly to the outer membrane (Boudreaux, 2010a).
Also in the membrane zone is the dense tubular system (DTS), a remnant of the
smooth endoplasmic reticulum of the megakaryocyte located near the microtubules.
Unlike the OCS, the DTS does not communicate with plasma or granule membranes.
DTS membranes contain cyclooxygenase and thromboxane synthase, and thus participate
in prostaglandin synthesis. The DTS is also a site for calcium sequestration by the
platelet; calcium movement is facilitated by ATPase pumps termed sarco/ endoplasmic
reticulum calcium ATPases (SERCAs), which are tightly coupled to plasma membrane
calcium ATPases (PMCAs). PMCAs function to move calcium ions to the extracellular
medium while SERCAs pump calcium ions into the DTS (Kovacs et al., 1997).
1.2.6.1

Dense granules
The dense granules or dense bodies, as their name implies, are electron dense

when viewed using an electron microscope, and serve as storage sites for adenine
nucleotides, serotonin, calcium, and inorganic phosphates (McNicol & Israels, 1999;
Rendu & Brohard-Bohn, 2001). Serotonin is actively transported from plasma into dense
granule cores, and the serotonin concentration within dense granules is 1000 times higher
than plasma concentrations. Dense granules contain 70% of the total calcium within
platelets. However, unlike the calcium pool within the DTS, this calcium pool is not
mobilized during platelet activation. Inorganic phosphates, calcium, serotonin, and
adenine nucleotides are held together tightly within dense granules as a result of
intermolecular forces, thus contributing to their stability and density (Skaer et al., 1974).
Dense granules also contain ganglioside GM3 and phospholipids including
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phosphatidylethanolamine, phosphatidylinositol, phosphatidylcholine, and sphingosine
(D. Chatterjee & Anderson, 1993).
The release of substances from dense granules is by exocytosis, a process that
requires Rab proteins and complex secretory machinery. Among the released constituents
are adenosine diphosphate/adenosine triphosphate (ADP/ATP), inorganic polyphosphate,
pyrophosphate, serotonin and Ca2+ (Nurden, 2011). Upon platelet activation, several
receptors in dense granule membranes become expressed on the plasma membrane as a
result of dense granule fusion with the surface. Some of these receptors are shared with
other granule membranes and with the plasma membrane (Boudreaux, 2010a).
1.2.6.2

Alpha granules
The alpha granules are the largest and most numerous of the platelet granules.

They are unique in terms of structure and packaging function and are the main storage
granule within platelets. Platelets contain from 40 to 80 alpha granules, each measuring
between 200 to 500 nm and enclosed by a membrane (Italiano & Battinelli, 2009).
Structurally, alpha granules are composed of two major compartments, a dark centrally
located nucleoid region and a peripherally located electron-lucent gray matrix region that
can be viewed at the electron microscopic level. The nucleoid region contains
proteoglycans, which confer stability to the granules, and it is where betathromboglobulin and PF4 are localized. Von Willebrand factor (vWF), multimerin, and
factor V colocalize within tubular structures located in the outer part of the gray matrix
region. Fibrinogen, thrombospondin, and fibronectin are primarily located in the gray
matrix region in an area between the nucleoid and outer gray matrix regions (Boudreaux,
2010a).

17

Alpha-granule proteins are derived from both megakaryocyte synthesis and
proteins that are endocytosed. Proteins that are synthesized by megakaryocytes fall into
two categories, those that are megakaryocyte-specific, such as β-thromboglobulin and
PF4, and those that are synthesized by other cells but are concentrated within platelet
alpha granules, such as factor V and platelet-derived growth factor (PDGF) (Berger et al.,
1993). The latter proteins are sometimes referred to as platelet-selective proteins. The
most well-recognized protein endocytosed by platelets is fibrinogen, with uptake being
mediated by the GPIIb-IIIa receptor. Proteins present in low levels within alpha granules,
such as albumin and immunoglobulin, are passively taken up by platelets and do not
require specific receptors (Boudreaux, 2010a).
Alpha-granule membrane proteins become expressed on the platelet surface after
platelet secretion as a result of the fusion of granules with the OCS or outer platelet
membrane. The most well-known alpha-granule membrane protein expressed on the
surface of activated platelets is P-selectin or CD62P (Larsen et al., 1989). Other proteins
present within alpha-granule membranes include GPIb-IX-V, GPIIb-IIIa, platelet and
endothelial cell adhesion molecule-1 (PECAM-1), vitronectin receptor, and GPIV
(Boudreaux, 2010a).
Alpha granules initially develop from budding vesicles containing neosynthesised protein cargo from the trans-Golgi network within megakaryocytes, from
where they mature into multivesicular bodies (MVBs), which can interact with the
endocytic vesicles. This vesicle trafficking and fusion involve coat proteins, adaptor
proteins, fusion machinery, and monomeric GTPases (Blair & Flaumenhaft, 2009;
Italiano & Battinelli, 2009). MVBs, which appear as a membranous sac containing
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numerous small vesicles, seem to provide a common sorting compartment for both alpha
granules and dense granules and are thought to also function as a sorting center to route
proteins into distinct classes of alpha granules (Italiano & Battinelli, 2009). Preformed
alpha granules are transported from the megakaryocyte body on microtubule tracks
within the pro-platelets; the granules are captured by the developing platelets prior to
their release into the circulation (Richardson et al., 2005). These processes are
accompanied by clathrin-mediated endocytosis of surface receptor-bound plasma proteins
(e.g. fibrinogen) while pinocytosis also occurs (e.g. albumin, IgG). Clathrin-dependent
endocytosis of fibrinogen continues throughout the platelet lifespan (Nurden, 2011).
Distinct subpopulations of alpha granules are clearly visible along proplatelets,
indicating that the segregation of proteins into distinct classes of alpha granules occurs
before proplatelet production initiates (Italiano et al., 2008). Alpha-granule traffic is
observed to be bidirectional along the proplatelets, as predicted from the mixed polarity
of proplatelet microtubules (Richardson et al., 2005). This bidirectional nature of granule
movement and the general slowness of traffic suggest that the objective of this transport
process is to disperse the cargo throughout proplatelets as well as to mix the various
granules/organelles with the proplatelet (Italiano & Battinelli, 2009).
1.2.6.3

Lysosomal granules
Lysosomal granules contain acid-dependent hydrolases including glycosidases,

proteases, and lipases. (Dell'Angelica et al., 2000). Lysosomal membranes contain
proteins that become exteriorized during the platelet release reaction. These membrane
proteins include lysosomal integral membrane protein (CD63) and lysosomal-associated
membrane proteins 1 and 2 (Febbraio & Silverstein, 1990), which are heavily
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glycosylated to protect them from hydrolytic enzymes stored within these granules
(Bentfeld-Barker & Bainton, 1982). Other membrane proteins mediate transport of ions
and amino acids across the membrane necessary for the maintenance of an acidic luminal
pH (Boudreaux, 2010a).
1.2.7

Platelet activation
Platelets have cell surface receptors that recognize signals from their environment

and communicate those signals to a complex network of biomolecules that include ions,
proteins, nucleotides and phospholipids (Boudreaux, 2010a). For example, receptors
recognize and bind subendothelial components such as collagen, fibronectin, laminin, and
thrombospondin (Bennett et al., 2009). When these and other molecules bind to platelet
receptors, they induce structural changes in glycoproteins on the platelet membrane
surface that then allow binding of proteins that mediate platelet adhesion and
aggregation. Binding of adhesive proteins to receptors promotes and enhances platelet
granule release, platelet aggregate and fibrin formation, and clot retraction (Boudreaux,
2010a).
Platelets respond to external stimuli by a series of signaling mechanisms and
conformational changes. These changes result in the formation of a stable platelet plug at
sites of injury and require both initiation and propagation of platelet activation. Initiation
is typically provided by exposed collagen and vWF in the vessel wall, and by the local
generation of thrombin once tissue factor/VIIa complexes have formed. Propagation
occurs when additional platelets are recruited into a growing hemostatic plug by released
or secreted secondary agonists such as TXA2 and ADP (Angelillo-Scherrer et al., 2001).
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The GPIb/IX/V complex is the major platelet receptor mediating interaction with
vWF and collagen. Through this binding, platelets adhere to the surface of the
subendothelium (Harvey, 2012; Karachaliou et al., 2015). This complex does not bind
circulating vWF, but only the molecules that have been immobilized within the
extracellular matrix, bound primarily to collagen (Harvey, 2012). Also, two other
receptors bind directly to collagen, GPVI immunoglobulin superfamily members and
GPIa/IIa (Karachaliou et al., 2015). These collagen receptors function both in adhesion
and as agonist receptors that activate platelets (Boudreaux, 2010a)
The receptor GPIIb-IIIa mediates platelet aggregation and also assists in early
stages of platelet adhesion to the subendothelium (Boudreaux, 2010a). Upon platelet
activation, the receptor undergoes a conformational change that enables it to bind
fibrinogen and vWF, allowing stable bridges between platelets (Karachaliou et al., 2015).
G protein-coupled receptors (GPCRs) are seven transmembrane spanning
signaling molecules. They are associated with a group of G proteins consisting of three
subunits termed alpha, beta, and gamma, and are classified into four families according to
their α subunits: Gi, Gs, G12/13, and Gαq (Neves et al., 2002). Platelets contain
representatives of all four of the known families of G proteins, and Gq, Gi, and G12 have
been shown to mediate the effects of agonists that activate platelets. Agonist receptors
may couple to one, two, or all three of these G proteins (Woulfe et al., 2001). Two
classes of GPCR, the purinoceptor 2 (P2) receptors, P2Y1 and P2Y12, bind ADP and
induce aggregation and thrombus growth (Offermanns, 2006). P2Y1 binding activates
phospholipase C (Jin et al., 1998), and binding to P2Y12 suppresses cAMP formation so
that activation can occur (Hollopeter et al., 2001; Zhang et al., 2001). ATP, on the other
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hand, acts through the ligand-gated P2X1 receptor and is an important co-factor both in
collagen-induced platelet aggregation and in epinephrine-mediated potentiation of the
response to low dose thrombin (Grenegard et al., 2008).
The activation of platelets by thrombin is mediated at least in part by cleavage of
proteinase-activated receptors (PARs). Four distinct PARs have been cloned, and PAR1,
PAR3, and PAR4 are activated by thrombin. Human platelets express PAR1 and PAR4,
and activation of either is sufficient to trigger platelet aggregation and secretion (Kahn et
al., 1999; Vu et al., 1991; Xu et al., 1998), whereas murine platelets express PAR3 and
PAR4, and thrombin signaling is PAR4-dependent (Nakanishi-Matsui et al., 2000). There
is little information about these receptors in platelets in dogs, in which these receptors
have mostly been studied in the vascular endothelium [e.g. (Ku & Zaleski, 1993;
Saifeddine et al., 2007)]. Studies with canine platelet cDNA sequences suggest that
canine platelets do possess PAR1, PAR3, and PAR4 receptors. The encoded amino acids
found were similar but not identical to either human or mouse platelet receptors
(Boudreaux et al., 2007).
Platelet activation leads to activation of phospholipase A2 and hydrolysis of
phospholipids (especially phosphatidylcholine) from the dense tubular system, releasing
arachidonic acid, which is then metabolized to TXA2 by the cyclooxygenase enzyme
pathway (Jurk & Kehrel, 2005). Phospholipase A2 in conjunction with an
acetyltransferase is also involved in generating platelet-activating factor, another agonist
that induces platelet aggregation (Brooks et al., 2009; Chilton et al., 1991).
The exposure of negatively charged phospholipids on the platelet surface is
another major effect of platelet activation and is crucial in assisting secondary
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hemostasis. Phospholipids are asymmetrically located in the platelet plasma membranes,
because of the presence of the Mg-ATP-dependent enzymes flippase and floppase.
Flippase is an inward-directed pump for phosphatidylserine (PS, negatively charged) and
phosphatidylethanolamine (neutral) that concentrates PS in the inner leaflet of the
membrane. Other neutral phospholipids, including phosphatidylcholine and
sphingomyelin, are transported to the outer membrane leaflet of platelets by floppase
activity (Burnier et al., 2009). The activation of platelets by agonists results in the
calcium-dependent activation of scramblase, which promotes unspecific bidirectional
redistribution of phospholipids across the bilayer, and inhibition of flippase activities.
These effects result in negatively charged phospholipids (primarily PS) being
translocated from the internal leaflet to the external leaflet of the plasma membrane
(Freyssinet & Toti, 2010; Key, 2010). PS on the surface binds positively charged Ca2+,
which also binds negatively charged carboxyl groups of coagulation factors. This binding
not only brings factors together to enhance interactions, but also helps to protect them
from inhibitors (Jurk & Kehrel, 2005).
Fibrinogen, vWF, and collagen binding induce platelet cytoskeleton
conformational changes. Binding to GPIIb/IIIa up-regulates phosphatidylinositols, in
particular, phosphatidylinositol (4,5) bisphosphate (Ptdlns(4,5)P2), as part of the outsidein signaling cascade (Goschnick et al., 2006). Ptdlns(4,5)P2 induces the recruitment of
several actin-modulating proteins, resulting in the interaction of the cytoskeleton with the
microdomains. This interaction is necessary for sustaining the forces necessary for
mediating clot retraction (Bodin et al., 2005). Collagen and vWF binding induce
circumferential bundles of microtubules to reorganize into linear arrays, and actin
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disassembles and reassembles as platelets form filopodia and spread (Boudreaux, 2010a;
Jurk & Kehrel, 2005). Adducin molecules dissociate from the ends of actin filaments,
allowing disassembly and reorganization of actin, promoted by gelsolin and cofilin. Actin
reassembly during the formation of filopodia and lamellipodia by activated platelets is
mediated by the actin-related protein 2/3 complex. Actin reassembly and myosin II
binding and activation are critical for platelet spreading, granule movement, granule
release, and clot retraction (Boudreaux, 2010a).
Upon activation, platelet granules undergo fusion and dissolution mediated by a
surrounding web of microtubules and microfilaments, eventually resulting in secretion.
The contents of dense bodies and granules are discharged into the OCS, which is
contiguous with the platelet surface (Rendu & Brohard-Bohn, 2001). Ruminant, equine,
and elephant platelets have minimal canalicular systems. Thus, granules fuse with the
external platelet membrane and release their contents directly to the platelet exterior
(Boudreaux, 2010a; du Plessis & Stevens, 2002). Platelet alpha-granule release occurs
more readily than dense granule secretion in response to weak agonists, but the
mechanisms leading to membrane fusion and secretion of the two granule types have
generally been assumed to be similar. Dense granule secretion is required for plateletplatelet interactions, whereas alpha granules appear to be central to platelet trafficking
with other cell types. P-selectin, for example, expressed after fusion of the alpha granule
with the platelet surface membrane, mediates activated platelet-leukocyte adhesion
(Rinder et al., 1993).
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1.2.8

Platelet selective activation and selective alpha-granule release
Human platelet alpha granules have been demonstrated to have differential

packaging and selective release of proteins (Battinelli et al., 2011; M. Chatterjee et al.,
2011; Italiano et al., 2008; Sehgal & Storrie, 2007; Villeneuve et al., 2009). It is not clear
how this differential distribution is achieved, but it seems to involve both subgroups of
granules and functional colocalization of the proteins within the granules. A study using
electron tomography of human platelets demonstrated not only morphologically different
alpha-granule subtypes, but also high spatial segregation of cargo within individual alpha
granules (van Nispen tot Pannerden et al., 2010). Even though these and other studies
suggest that proteins with antagonistic functions are separately packaged, which would
seem a reasonable explanation for functional differential release, the exact distribution of
the alpha-granule proteins is still unresolved. One group of researchers reported a study
with pair-wise colocalization comparisons between several angiogenic factors and
proteins synthesized and endocytosed and failed to demonstrate any clear pattern of
distribution (Kamykowski et al., 2011).
Regardless of how these proteins are packaged and distributed in subtypes of
granules and/or in different areas within individual granules, there is a strong body of
evidence for human and animal platelet selective activation and granule release. A classic
example of this selectivity is the activation of PAR1 and PAR4 in human and rat
platelets. When activated through PAR1, platelets are shown to release contents with
proangiogenic potential, such as VEGF and stromal cell derived factor-1α (SDF-1α).
When PAR4 is activated, the result is the opposite, with the release of antiangiogenic
factors, such as endostatin and PF4 (M. Chatterjee et al., 2011; Italiano et al., 2008; Ma et
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al., 2001; Ma et al., 2005). It is still unknown if canine platelets have functionally active
PAR1 and PAR4, or if they participate in the selective release of alpha-granule contents.
ADP and TXA2 have also been demonstrated to selectively stimulate human platelets.
ADP induces a proangiogenic releasate, and TXA2 an antiangiogenic releasate (Battinelli
et al., 2011).
Interaction with tumor cells was also shown to induce selectively proangiogenic
factor release. Incubation of a breast cancer cell line with platelets results in releasates
that have increased VEGF content (measured by ELISA), present high levels of
proangiogenic factors such as epidermal growth factor (EGF) and PDGF (by angiogenic
antibody array), and are able to induce endothelial cell proliferation. None of these
findings are seen with tumor cell supernatant alone (Battinelli et al., 2011).
1.2.9

Platelet-derived angiogenic factors as potential cancer biomarkers
Tumor growth and progression are dependent on vessel growth, which is

coordinated by pro- and antiangiogenic molecules. Proangiogenic factors include VEGF
and bFGF), both of which are peptides produced by tumor cells, supporting tissues,
associated inflammatory cells and the vascular endothelium. Proangiogenic activity is
counter-regulated by inhibitors of vascular growth such as thrombospondin-1 (TSP-1),
endostatin, PF4, and angiostatin. Recently, some of these angiogenic related proteins
have been evaluated as diagnostic and prognostic tools. Similarly, since platelets are
known to capture and concentrate molecules that modulate angiogenesis, measurement of
these molecules within platelets is also being studied as a cancer prognostic marker.
Proteomic analysis of platelets in rats bearing actively growing tumors reveals
higher levels of VEGF, bFGF and PGDF, and lower levels of the angiogenesis inhibitor
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endostatin, reflecting a proangiogenic tumor environment (Cervi et al., 2008; Klement et
al., 2009). It is postulated that the presence and state (dormant vs. progressive) of a tumor
will be reflected by the balance of angiogenesis-modulating factors contained within
circulating platelets. A microscopic, dormant tumor will be reflected by an imbalance
with a shift towards antiangiogenic potential, and a large vascularized, growing tumor
will be associated with proangiogenic platelets (Almog & Klement, 2010).
In humans, circulating levels of angiogenic proteins are profoundly changed
malignant neoplasms or metastatic diseases. Patients with metastatic disease have higher
serum levels of VEGF and lower levels of antiangiogenic proteins compared to healthy
individuals (Wiesner et al., 2010). In one study, patients with pancreatic cancer had
higher levels of proangiogenic proteins (VEGF, PDGF-AA, EGF, angiopoietin-1).
Whereas high PDGF-AA in these patients correlated with poor survival, while high
PDGF-BB, angiopoietin-1, and VEGF correlated with a favorable prognosis (Rahbari et
al., 2011). However, in another study in patients with pancreatic cancer, affected
individuals not only increased plasma levels of proangiogenic VEGF but also increased
plasma antiangiogenic TSP-1 compared to healthy individuals (Starlinger et al., 2011).
Studies in hepatocellular carcinoma patients showed increased serum VEGF, PDGF, and
the antiangiogenic molecule angiostatin compared to healthy subjects. Furthermore, high
VEGF and angiostatin correlated with worse progression-free survival rates and higher
stages of disease (Suh et al., 2014; Talaat et al., 2014). These studies illustrate that,
although the presence of cancer certainly influences circulating levels of angiogenesisrelated proteins, the type (anti- or pro-) of proteins that is increased and the prognostic
value of measurement of these protein varies drastically among types of cancer. Studies
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measuring levels of angiogenic proteins in the platelets of human patients are still rare.
One study evaluated VEGF levels in platelet lysates, which were found to be higher in
patients with different types of metastatic cancer compared to healthy controls (Niers et
al., 2011).
Several studies in dogs similarly suggest the potential of measuring circulating
VEGF levels for determining prognosis and the presence of malignancy. Canine
lymphoma patients were found to have higher serum and plasma VEGF levels than
healthy controls, and these elevated higher VEGF levels were correlated with higher
tumor grade and lower disease-free intervals (Aresu et al., 2014; Gentilini et al., 2005).
Likewise, in dogs with osteosarcoma, lower serum VEGF levels were found to correlate
with higher disease-free intervals (Thamm et al., 2008). Serum VEGF was also reported
to be higher in dogs with hepatoid gland epithelioma in comparison with the control
dogs. Furthermore, the VEGF levels decreased with remission and increased with relapse
(Sobczynska-Rak & Brodzki, 2014). In dogs with oral neoplasms, serum VEGF levels
were found to be higher in animals with malignant neoplasms than in animals with
benign lesions. Patients with benign tumors had VEGF levels higher or equal to those of
healthy controls (Sobczynska-Rak et al., 2014). In dogs with malignant mammary
neoplasia, serum VEGF levels were reported to be higher than in healthy animals, and
high levels correlated with highly vascularized tumors, metastasis, and lower survival
time (Moschetta et al., 2015). Although there are no studies in dogs that have measured
angiogenic proteins specifically in platelets, the level of VEGF in thrombin-activated
platelet rich plasma was measured in dogs with lymphoma, and the level correlated with
a high tumor grade. A high microvessel density in the tumor tissue also correlated with a
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high tumor grade (Zizzo et al., 2010). Thus, in summary, although there is no consistent
published information about angiogenic protein content in canine platelets, it is
reasonable to expect that these proteins will be present in canine platelets, and that, as in
humans and rats, measurement of platelet angiogenic proteins could have value as a
potential cancer biomarker.
1.2.10 Effect of platelets in cancer development and metastasis
Neoplastic tissues contain leaky vasculature with a turbulent, nonphysiological
blood flow. Platelets can be activated within these pathological vessels due to because of
contact with subendothelial structures, and because of nonlaminar blood flow. The
resulting platelet-released cytokines have been suggested to induce proliferation and
migration of tumor cells and angiogenesis (Buergy et al., 2012).
There is a strong body of evidence that mouse and human platelets promote
cancer cell migration and assist in metastasis. In the late 1960’s it was shown for the first
time, in a murine carcinoma model, that thrombocytopenia offers protection from
metastasis. Mice with decreased platelet levels induced by neuraminidase or antiplatelet
serum injection had decreased metastasis rates that correlated with the low platelet
numbers. Moreover, inhibition of metastasis was reversed by platelet transfusion (Gasic
et al., 1968). Then, in the early 1970’s, one study evaluated the relationship between
platelets and several murine and human tumor cell lines. The cell lines that were able to
aggregate platelets were more metastatic, with the metastatic foci more concentrated in
the lung. The metastatic process was highly inhibited by thrombocytopenia. Additionally,
it was observed that tumors that did not aggregate platelets had fewer metastases in the
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lung and instead, the foci of cancer metastasis had a wider body distribution (Gasic et al.,
1973).
Since the publication of those two innovative studies, several other experiments
have explored the participation of platelets in cancer development. Anti-platelet antibody
given to mice before tumor cell injection was shown to consistently decrease the number
and size of lung metastases of carcinomas and melanoma (Pearlstein et al., 1984). Mice
with loss of platelet activation, which were injected with melanoma and lung carcinoma
cell lines, had an intense reduction in metastases. It was further observed that adequate
platelet function protected tumor cells from natural killer cell-mediated destruction
(Palumbo et al., 2005). Additionally, the absence of platelet GPIb-IX resulted in
decreased lung metastasis in mice inoculated with melanoma cells (S. Jain et al., 2007).
Finally, it has been suggested that inhibition of platelet function by aspirin might play a
role in decreasing cancer malignancy. Aspirin has been shown to decrease cancer
invasion in animal models (Tsai et al., 2009) and to have a protective potential against
colon cancer in humans (Kune et al., 1988). Although aspirin has been shown to directly
alter tumor cell invasion, one of the other mechanisms of this tumor inhibition may be
related to aspirin’s inhibition of platelet function.
Experiments using in vitro incubation of platelets with tumor cells have also
demonstrated the ability to promote a malignant phenotype. Mice inoculated with colon
carcinoma and breast carcinoma cell lines that were previously incubated with platelets
had an increased rate of lung metastases. Platelet treatment also induced a morphologic
modification in the tumor cells, which differentiated into a more invasive, mesenchymallike phenotype. Activation of transforming growth factor-TGF- and NK-kB
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pathways appear to be involved in the promotion of metastases by platelets since ablation
of signaling in platelets prevents metastasis. Platelet-derived TGF-1 possibly induces
tumor cell extravasation and invasion into the lung parenchyma. Platelet-tumor cell direct
contact synergizes with TGF- signaling (Labelle et al., 2011). Another study showed
that lung carcinoma cells exposed to platelet-derived microparticles (vesicles that shed
from platelets after activation, and that contain several adhesive proteins expressed
during activation) had increased metastatic potential. Exposed tumor cells exhibited
increased proliferation, invasion, and angiogenic factor expression (Janowska-Wieczorek
et al., 2005). Platelets have been shown to stimulate transendothelial migration of
melanoma and lung carcinoma cell lines in vitro, and this effect was demonstrated to
depend on the release of nucleotides and dense granule secretion. Likewise, defective
dense granule secretion by platelets impaired tumor cell metastasis in vivo (Schumacher
et al., 2013). These results show that platelets are able to affect tumor cells in vitro, and
affect the ability of these cells to extravasate from the blood vessel and seed tissue.
1.2.11 Activation of platelets by tumor cells
The study from Gasic and collaborators in 1973 that demonstrated the effects of
platelets on metastasis in several murine tumor cell lines also evaluated mouse platelet
aggregation stimulated by these cell lines. Of nine mammary carcinoma cell lines, four
lines were shown to aggregate platelets. Nine out of 16 sarcomas and one of two
melanomas were also able to trigger platelets aggregation in vitro. None of the evaluated
lymphoma, plasmacytoma, and leukemia cell lines exhibited platelet aggregation
properties (Gasic et al., 1973). Human adenocarcinoma cell lines and anaplastic mouse
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tumors have been shown to aggregate human and rabbit platelets (Pearlstein et al., 1981;
Radomski et al., 1991). Moreover, one study demonstrated that a human osteogenic
sarcoma cell line induced human platelet aggregation by itself and that another cell line
induced aggregation after preincubation of the platelet sample with epinephrine.
Leukemia and lymphoma cells, in contrast, were not able to aggregate platelets (Mehta et
al., 1987). These studies indicate that, although the ability to activate platelets might vary
among cancer cell lines, it is certain that some cancer cells do activate platelets. Also, it
seems that the ability tumor cells to activate platelets may be related to the
malignancy/spreading potential of a particular tumor cell line.
1.2.12 Dogs as models for cancer research
Mice are the most frequently used research model for cancer and other genetic
diseases and have several advantages compared to other species. Mice have short
gestation times and are small, making their generation time relatively rapid, and they are
inexpensive to maintain compared to other mammals. Moreover, their genetics are highly
defined and readily manipulated. The mouse genome has recently been sequenced,
essentially in its entirety, and detailed comparative maps of the human and mouse
genomes have been developed (Kusewitt, 2012; Rowell et al., 2011).
However, mouse models of cancer have limitations. The most notable are that
tumors arise spontaneously in humans, but are almost always induced in mouse models.
Also, whereas human disease is polygenic, genetic manipulations in mouse models often
involve one or a few genes and/or environmental conditions that affect the expression of
specific genes in an inbred mouse line with undetermined human relevance (Karlsson &
Lindblad-Toh, 2008). Moreover, during therapeutic drug tests, the vast majority of agents
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that are found to be successful in mouse animal models end up failing in human trials,
which demonstrates a critical translational limitation (Mak et al., 2014). Examples of this
limitation that contribute to the difference in trial results include the facts that mice can
tolerate higher drug concentrations than human patients, and that mouse bone marrow
may be less sensitive to many cytotoxic agents (Teicher, 2009).
In contrast, naturally occurring cancers in dogs mimic and represent biologically
complex conditions in a way that is not possible in laboratory-bred mice. Similar
environmental, nutritional, age, sex, and reproductive factors lead to tumor development
and progression in both human and canine cancers (Fenger et al., 2014). Additionally,
dogs are uniquely suited as animal models for complex human diseases such as cancer
because of their phenotypic diversities. The genetic structure of dog populations in breeds
offers many advantages for genetic disease analysis. Breed creation has inadvertently
selected for many mutations that are associated with specific traits and diseases (Rowell
et al., 2011). Also, the biological behavior and response to treatment of many of the
canine spontaneous malignancies are similar to those seen in humans (MacEwen, 1990;
Withrow & Wilkins, 2010). Unlike mice, which have a much shorter lifespan, the time
course of tumor development is sufficiently long in dogs to allow meaningful comparison
of response to different treatments (Kusewitt, 2012). For all these reasons, the dog model
may also prove invaluable in research and development on cancer drugs (Khanna et al.,
2006). Finally, another advantage of the use of dogs in research is the fact that they are
relatively large and provide abundant tumor tissue for diagnostic and experimental
purposes (Kusewitt, 2012).
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Although investigations of the relationship between canine platelets and cancer
are scarce, since cancer and other diseases in dogs have many similarities to human
diseases, it is reasonable to believe that platelets will exert an important role in cancer
development and growth in dogs, as has been documented in humans. There are reports
that suggest that there is an effect of platelets in cancer in dogs. In dogs with
thrombocytosis, neoplasia was reported to be the most common associated disorder (34%
of cases) (Neel et al., 2012). Additionally, dogs with malignancies have been shown to
have hyperaggregable platelets in comparison to healthy dogs (McNiel et al., 1997).
1.3

Hypothesis, objectives, and dissertation outline
The interaction between platelets and cancer has great potential for the

exploration of mechanisms of cancer growth, biomarkers, and therapeutic candidates. In
veterinary medicine, apart from the use of the laboratory mouse model, this field is still
largely unexplored. As discussed in this review, canine cancer biology has many
similarities to human cancer biology, and the dog is, therefore, a promising candidate for
a research model for exploring several aspects of the relationship between cancer and
platelets. Additionally, veterinary medicine would greatly benefit with the development
of this new niche of canine cancer research.
Thus, as a preliminary step towards better understanding the dog as a cancer
model, the objective of this dissertation was to evaluate the interaction of canine platelets
and tumor cells. The main hypothesis is that canine platelets are similar to human and
murine platelets, and will interact with tumor cells, resulting in a change in the behavior
of these cells.
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In an effort to test this hypothesis, several experiments were performed and are
described in the next chapters. In Chapter Two, a study utilizing platelet
immunofluorescence is reported and provides evidence that canine platelets have
selective packaging and different alpha-granule subtypes, as shown in mice and humans.
This information is vital because it suggests that canine platelets are similar in this
respect to human and mouse platelets, and it supports the possibility that canine platelets
can also be selectively activated. The results in chapter three demonstrate platelet
activation by canine osteosarcoma and mammary carcinoma cells as detected by platelet
aggregometry, demonstrating an in vitro effect of canine cancer cells on canine platelets,
and suggesting that tumor cells likely affect platelet function in vivo. Chapter Four
describes experiments that demonstrate an inhibitory effect of canine intact platelets and
fractions on the migration of canine osteosarcoma and mammary carcinoma cell lines. In
Chapter Five, results show that platelet releasates derived from activation by different
agonists produce different effects on the migration of tumor cells. Chapter Six reports
that platelets can downregulate EMT transcription factors in canine cancer cells. Lastly,
in the seventh chapter, conclusions derived from these studies, and possible future
directions for this research field, are delineated.
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CHAPTER II
EVIDENCE OF SELECTIVE PACKAGING AND DIFFERENT ALPHA-GRANULE
SUBTYPES IN CANINE PLATELETS

Reprinted from Journal of Comparative Pathology 147(4), Curotto S, Lunsford K,
Smith W, Thomason J, Bulla C, 499-502, Copyright (2012). doi:
10.1016/j.jcpa.2012.02.007
2.1

Introduction
Platelets are circulating megakaryocytic cytoplasmic fragments required to

maintain the vascular integrity and prevent hemorrhage. They play important roles in
many processes including thrombosis, inflammation, wound healing, and angiogenesis.
Platelet function is dependent on hundreds of bioactive proteins and other mediators that
are released upon activation, principally by secretion of alpha-granule contents, which is
the major storage vesicle for secreted proteins (Nurden, 2011). Human and mouse
megakaryocytes are able to selectively package molecules within different alpha-granule
subsets. Similarly, molecules taken up by circulating platelets can also be selectively
sorted and stored (Chatterjee et al., 2011; Italiano et al., 2008; Sehgal & Storrie, 2007).
Dogs naturally develop several conditions that share histopathological
characteristics, genetic alterations, and biologic behavior similar to comparable disorders
in humans. Not only do dogs share their environment with humans, but also natural
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disease progression tends to occur more rapidly due to the canine’s shorter life span. This
makes the dog an attractive model for the study of naturally occurring disease,
particularly in the areas of hemostasis, inflammatory diseases, and cancer biology. Our
aim in this work was to test the hypothesis that differential packaging of proteins in
distinct α-granule subtypes, as observed in human and murine platelets, also occurs in
canine platelets. We looked at von Willebrand factor (vWF) and fibrinogen, which are
important adhesive proteins found in platelets α-granules that contribute to hemostasis
during vascular injury.
2.2

Material and methods
Three healthy female intact Walker hound dogs were used in this study. The dogs

were not exposed to any drugs or vaccines for at least two months prior to study
commencement. Normal health status was established based on the results of physical
examination, buccal mucosal bleeding time, complete blood count (including manual
platelet count), serum biochemistry, urinalysis, prothrombin time, partial thromboplastin
time, vWf antigen testing (ELISA method), heartworm testing, and rickettsial and
Babesia serology. Animal use was approved by the Mississippi State University
Institutional Animal Care and Use Committee and was in compliance with the
requirements at a facility accredited by the American Association for Accreditation of
Laboratory Animal Care.
Blood was collected into EDTA, mixed immediately with an equal volume of 4%
paraformaldehyde in phosphate-buffered saline (PBS), and fixed for two hours at room
temperature. Platelet-rich plasma (PRP) supernatant was created by centrifugation at
1,200 × g for two minutes. The PRP was washed and resuspended in PBS with 2%
51

paraformaldehyde and fixed for 30 minutes at room temperature. The PRP was pelleted
and resuspended with 1% bovine serum albumin (BSA) in PBS.
A cytospin was performed with 40 µl of platelet-rich suspension at 750× g for 5
minutes. Platelets that adhered to the slide were permeabilized with ice-cold methanol at
4°C for 5 minutes and blocked with 1% BSA in PBS for one hour. The platelets were
incubated for one hour at room temperature with sheep polyclonal IgG anti-canine vWF
and mouse monoclonal IgM anti-canine fibrin/fibrinogen antibodies (Thermo Fisher
Scientific Inc., Waltham, Massachusetts, USA). The slides were washed and then
incubated with FITC-conjugated rabbit polyclonal anti-sheep IgG (vWF) (Abcam plc.,
Cambridge, Massachusetts, USA) and Cy3 conjugated goat anti-mouse IgM
(fibrin/fibrinogen) (Millipore, Billerica, Massachusetts, USA). The slides were washed
with PBS-Tween 20 three times for 5 minutes after each staining.
Fluorescent images were acquired using a Zeiss LSM 510 Confocal Laser
Scanning Microscope (Carl Zeiss Microimaging, Inc., Thornwood, New York, USA)
with an Inverted Zeiss Axiovert 200 M Light microscope and a plan apochromat 100
X/1.40 NA oil objective lens. The FITC/TRITC (Fluorescein/Rhodamine/Transmission)
filter set was used in Single and Multi Track channel mode imaging. Excitation
wavelengths of 488nm/543nm and Long Pass (LP) emission wavelengths of 505 nm
(green) and 560 nm (red) were acquired at a 1024x1024 pixel format for imaging
purposes.
2.3

Results
In resting canine platelets, the majority of platelet vWF (green fluorescence) was

located in α-granules that were distinct from the alpha granules containing platelet
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fibrinogen (red fluorescence). There was minimal colocalization (yellow fluorescence) of
vWF and fibrinogen within alpha granules (Fig. 2.1 and 2.2). These results indicate that,
similar to humans and mice, dogs selectively package proteins needed for hemostasis in
platelet alpha granules, and thus have different subsets of platelet alpha granules.

Figure 2.1

Double immunofluorescence microscopy of resting canine platelets using
antibodies against (A) von Willebrand factor and (B) fibrinogen. (C) Color
merge.

Figure 2.2

Color merges of double immunofluorescence microscopy of resting canine
platelets using antibodies against von Willebrand factor and fibrinogen.
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2.4

Discussion
Von Willebrand factor is synthesized by megakaryocytes in the bone marrow,

while fibrinogen is synthesized by other cells and becomes internalized via endocytosis
by both the megakaryocytes and platelets (Sehgal & Storrie, 2007). The mechanism by
which differential distribution is achieved is not well established. In humans and mice, αgranule ontogenesis is shown to occur in megakaryocytes with the budding of small
vesicles containing neo-synthesized protein cargo from the Golgi network. They then
mature into multivesicular bodies (MVB) which are membranous sacs containing
numerous small vesicles. The MVB can interact with the endocytic vesicles and provide a
common sorting compartment for both alpha and dense granules. Furthermore, it is
hypothesized that MVBs also function as a sorting hub to route proteins into distinct
classes of alpha granules (Italiano & Battinelli, 2009). The transport of the alpha granules
to the developing platelets happens on microtubule tracks in the megakaryocyte body
within the pro-platelets, but the mechanism is also shared by the vesicle trafficking of
clathrin-mediated endocytosis of surface receptor-bound plasma proteins and pinocytosis
(Nurden, 2011; Richardson et al., 2005).
The different sources of vWF and fibrinogen contained in platelets would
probably be a rational explanation for the reason they are packaged in different granules.
This explanation, on the other hand, does not hold true among angiogenic factors shown
in human platelets. For example, endostatin, an anti-angiogenic factor, and the proangiogenic vascular endothelial growth factor are both taken up by platelets and have
been shown to be packaged in different alpha-granules subsets (Italiano et al., 2008;
Klement et al., 2009).
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Although the selective packaging is well accepted, recently a study (Kamykowski
et al., 2011) failed to demonstrate any pattern of distribution between several angiogenic
factors and proteins (synthesized and endocytosed) in a pair-wise colocalization setup.
These findings bring up important questions about the regulation of this process, which is
poorly understood.
Functionally, the differential distribution of proteins within diverse α-granules
subsets supports the selective release of these proteins. Under specific stimuli, human
platelets are able to selectively release α-granules containing either fibrinogen or vWF
(Sehgal & Storrie, 2007). Physiologically, such regulation can be explained by different
thrombin levels found during hemostasis and its capacity to activate different thrombin
receptors (protease activated receptors, PAR) that are concentration dependent. This
mechanism was particularly described in relationship to its regulation of angiogenic
factor release. In the early phases of wound healing or tissue injury, thrombin levels are
low and PAR-1, which has a high affinity for thrombin, is then activated, resulting in the
release of pro-angiogenic proteins. In a later stage, with the concentration of thrombin
increased, the low-affinity receptor PAR-4 is also activated, resulting in the release of
anti-angiogenic factors (Almog & Klement, 2010; Italiano et al., 2008). Although this
mechanism has also been shown to be elicited by other platelet receptors stimulated by
different agonists in humans and rats (Battinelli et al., 2011; Chatterjee et al., 2011;
Italiano et al., 2008; Ma et al., 2001; Ma et al., 2005), the cellular pathways involved in
its regulation and the impact of differential release of proteins in tissue regeneration and
angiogenesis remain poorly understood.
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In conclusion, these findings provide important evidence that canine platelets
contain different alpha-granule subtypes, which suggests that selective protein packaging
occurs during canine platelet ontology. As little is known about the mechanisms for
selective packaging or release of alpha-granule proteins in dog platelets, this is an
important step towards a better understanding of the role of the platelet in hemostasis,
thrombosis and wound healing, as well as the platelet’s role in angiogenic processes.
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CHAPTER III
CANINE CANCER CELLS ACTIVATE PLATELETS

3.1

Introduction
Platelets are small circulating cytoplasmic fragments that are crucial in the

promotion of primary hemostasis and support of coagulation. However, besides these
well-known functions, platelets also participate in a vast array of other physiological and
pathological phenomena in the body. These include their involvement in cancer biology,
which has long been studied in humans and mice. One of the ways platelets are shown to
be involved in neoplastic disorders is that cancer cells can directly interact with and
activate platelets, and this interaction is shown to promote cancer malignancy and
progression (Menter et al., 2014).
In dogs, studies evaluating the relationship between cancer cells and platelets are
scarce, and the effects that tumor cells can have on platelets in these animals are
unknown. However, despite this lack of information, it is reasonable to speculate that
platelets will play an important role in cancer development and growth in the dog since
cancer in dogs has many similarities to human cancer. There are a few studies that
support the idea that platelets and cancer are interconnected in dogs. For example, dogs
with thrombocytosis have been reported to have neoplasia as the most common
underlying disorder (Neel et al., 2012). Furthermore, dogs with malignancies have been
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shown to have hyperaggregable platelets in comparison to healthy dogs (McNiel et al.,
1997).
In order to better understand the crosstalk between cancer cells and platelets in
dogs, in this study was to evaluate whether cancer cells could activate and, as a
consequence, induce aggregation of canine platelets. We assessed the response of platelet
rich plasma to cultured canine cancer cells using light transmittance aggregometry.
3.2
3.2.1

Material and methods
Experimental design
We utilized three canine osteosarcoma cell lines (OSCA-8, OSCA-40, and

OSCA-78) and one canine mammary carcinoma cell line (CMT-28) that were previously
developed from dogs with spontaneously occurring cancers (Scott et al., 2011; Wolfe et
al., 1986). Platelets were isolated from the whole blood of healthy, young adult, female,
Treeing Walker Coonhound dogs (Marshall BioResources, North Rose, NY, USA and
Covance, Princeton, NJ, USA).
Aggregation studies were performed in freshly prepared platelet-rich plasma
(PRP). Before the experiments with cancer cells were started, optimization of the use of
PRP in the aggregometer in our laboratory needed to be performed. For this purpose,
methods of blood collection and platelet preparation were tested and optimized. Then,
platelet aggregation in response to commonly used agonists was evaluated, and dose
curve response experiments were performed, when applicable. Receptor antagonists were
also tested in this phase of the study. Although the methodology and results of the
experiments evaluating canine platelet aggregation in response to different agonists are
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described in this report, only the final optimized platelet preparation protocol is presented
here.
In every aggregation experiment, assay duplicates were done for each agonist or
cancer cell treatment (one in each channel, at the same time), and the average of these
duplicates was used as the experimental unit for that group. Positive controls were
performed at the beginning and end of every run, to evaluate platelet responsiveness
throughout the experiment length. Likewise, appropriate negative controls were
performed where applicable. The resulting averages of percent maximum aggregation,
slope, and area under the curve were obtained in all samples. Pair-wise comparisons were
performed using ANOVA followed by Tukey’s or a t-test at the significance level of
0.05.
3.2.2

Cancer cell culture
Cells were maintained in Dulbecco’s Modified Eagle’s Medium containing 5%

glucose and supplemented with 10% fetal bovine serum (FBS) (Gibco, Grand Island, NY,
USA), 0.1 mg/ml Primocin (InvivoGen, San Diego, CA, USA), and 10 mM HEPES
buffer solution (Sigma-Aldrich, St Louis, MO, USA). The cells were seeded in T75
flasks, incubated at 37°C, 5% CO2 (Thermo Scientific, Waltham, MA, USA), and split
when they reached about 80% confluence.
3.2.3

Blood collection and sample preparation
Dogs had food withheld overnight before blood collection. Nine milliliters of

blood were collected from the jugular veins into 10 ml plastic syringes containing 1 ml of
either citrate 3.2% (for experiments with platelet agonists) or heparin 20 U/ml (for cancer
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cell activation experiments). After being drawn and mixed with the anticoagulant, the
blood was immediately transferred to a 15 ml Falcon tube. Proper care was taken to
ensure blood collection with minimal trauma and gentle blood and PRP handling, in order
to avoid in vitro platelet activation, in every step of the sample preparation. Blood
samples from traumatic blood collection procedures, or samples that were hemolyzed,
lipemic, or containing fibrin clots were discarded prior to any further experimentation.
Platelet-rich plasma was prepared by centrifuging the blood in Falcon tubes for 5
minutes, at 300 × g, without the use of the centrifuge brake. The entire upper layer was
collected after centrifugation, and the process was repeated once or twice, depending on
the amount of PRP obtained for each specific dog.
Platelet-poor plasma (PPP) was obtained by centrifuging the remaining blood for
10 minutes at 2,000 × g. This PPP was used for PRP dilution to reach a platelet
concentration of 200,000/μl, and for the aggregometer baseline setting.
Leukocytes (peripheral blood mononuclear cells [PBMC]) were isolated by
density centrifugation with Histopaque-1077 (Sigma-Aldrich, Saint Louis, MO)
following the manufacturer’s instructions. The final samples were resuspended in PBS.
3.2.4

Platelet aggregometry
The response of platelets to the addition of agonists or cancer cells was assessed

by light transmittance (turbidimetric) aggregometry, in a double channel optical
aggregometer (Chrono-log Corporation, Havertown, PA), with stirring at 1,200 rpm at
37°C. Two hundred and fifty microliters of PRP were placed in cuvettes containing
stirring bars. The samples were allowed to warm up for at least 5 minutes. Once placed in
the channel, samples were left for 1 to 2 minutes to stabilize the light transmittance, and
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the baselines were set with the non-aggregated PRP (0% aggregation) and PPP (100%
aggregation). If antagonists were used, they were added to PRP in the cuvettes placed in
the channels and incubated for 2 minutes before adding the agonist or cancer cells. After
addition of agonists or cancer cells, samples were left running for approximately 5 to 10
minutes, depending on the experiment and according to the time that each curve reached
maximum aggregation and stabilized.
In the beginning of the experiments, canine platelet aggregation was evaluated in
PRP pooled from two dogs, in response to different concentrations of several agonists
with or without an antagonist pre-incubation. Adenosine diphosphate (ADP), collagen
type I (from equine tendon), and arachidonic acid (AA) were purchased from Chrono-log
Corporation (Havertown, PA). The thromboxane A2 (TXA2) receptor agonist U46619
was from Tocris Bioscience (Ellisville, MO, USA), and gamma-thrombin was purchased
from Haematologic Technologies (Essex Junction, VT, USA). Activating peptides for the
protease-activated receptor (PAR)-1 (TFLLR-NH2) were acquired from Tocris
Bioscience and for PAR-4 (AYPGKF-NH2) from Abgent (San Diego, CA). Antagonists
of ADP receptors P2Y1 (MRS 2279) and P2Y12 (PSB 0739); and PAR-1 (SCH 79797)
and PAR-4 (tcY-NH2) were from Tocris Bioscience.
For testing aggregation by cancer cells, PRP from individual dogs was used.
Cancer cells were detached by citric saline (135 mM KCl, 15 mM sodium citrate), and
resuspended in PBS, in three different concentrations: 10,000, 20,000, and 30,000
cells/μL. Then, twenty-five microliters of these cell suspensions were added to the PRP,
and final concentrations were 1,000, 2,000, and 3,000 cells per microliter, which resulted
in final ratios of 1/200, 1/100, and 1/66 cancer cell per platelet, respectively. From here
63

on, these three amounts of cancer cells are going to be referred to as concentrations 1, 2,
and 3, respectively. Preincubation with the antagonist of the ADP receptor P2Y12 was
also tested in these experiments. Aggregation with collagen and ADP were included as
positive controls in every run. Isolated autologous PBMCs resuspended in PBS were used
as a negative control for platelet aggregation, and were added at a concentration of 1,000
cells/μl in the PRP.
3.3
3.3.1

Results
Platelet aggregation response to several agonists
We tested several agonists in various concentrations for their ability to aggregate

canine PRP. Figure 3.1 shows the dose-response curves of platelet maximum percentages
of aggregation when using ADP, collagen, and gamma-thrombin. ADP resulted in dosedependent irreversible aggregation at 10 μM and higher concentrations. Aggregation was
reversible when concentrations lower than 10 μM were used. A secondary wave of
aggregation was never observed, even when using the lower concentrations of ADP. The
P2Y1 receptor antagonist MRS-2279 completely inhibited ADP-induced platelet
aggregation at 10 μM and the P2Y12 receptor antagonist PSB-0739 induced a complete
inhibition at 160 μM. Collagen caused a permanent shape change at 5 μg/mL and at 10
μg/mL induced 80% aggregation. Higher concentrations did not result in further change
in many variations maximum aggregation, and 90% aggregation was consistently
achieved with 20.7 μg/ml. Similar to the collagen response pattern, gamma-thrombin
induced a shape change at 2.5 nM and maximal aggregation was achieved with
concentrations starting at 15 nM. After passing this threshold, the response to gammathrombin was also non-dose dependent.
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In order to explore the role of thrombin receptors in canine platelet aggregation,
we used PAR-1 and 4 activating peptides, and PAR antagonists plus gamma-thrombin to
aggregate PRP. However, we failed to demonstrate the function of these receptors with
the reagents utilized. PAR agonists were not capable of aggregating platelets and PAR
antagonists did not interfere with aggregation by gamma-thrombin. We used the
maximum concentrations possible of each of the reagents, which were 100 μM PAR-1
agonist peptide, 1 mM PAR-4 agonist peptide, 30 μM PAR-1 antagonist, and 264 μM
PAR-4 antagonist.
Platelet shape change, which is detected by a transient increase in light
absorbance by the platelet sample, was observed with the thromboxane receptor agonist
U46619 at a range of different concentrations from 100-400 μM. However, platelet
aggregation was only observed with 4 mM of reagent. Similarly, shape change was
observed with 2 mM of AA, but aggregation was observed only with 8 mM.
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Figure 3.1

Dose response curves of percent aggregation with ADP, collagen, and
gamma-thrombin

Citrated canine platelet rich plasma was activated by different concentrations of
adenosine diphosphate (ADP), collagen, and gamma-thrombin, and maximum percent
aggregation was measured by light transmittance aggregometry.
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3.3.2

Platelet aggregation by cancer cell lines
We used three different concentrations of each of the cell lines to aggregate

canine PRP. For most of the cell lines, there were no significant differences in the
resulting averages of the percentage of maximum platelet aggregation, slope, or area
under the curve (AUC) amongst these three concentrations (Fig. 3.2). The only cell that
resulted in some differences in parameters was OSCA-40. In this cell line, concentration
1 resulted in a significantly higher maximum aggregation percentage when compared to
concentration 3 (P < 0.05), and the slope of concentration 2 was significantly higher than
concentration 3 (P < 0.01).
When compared to aggregation parameters obtained from the addition of PBMC
to platelets (control), all cell lines had significantly higher maximum aggregation
percentage and slope in at least one of the concentrations used. Figure 3.3 shows the
average parameters obtained when concentration 1 of each cell line was added to
platelets, compared to the control. This concentration was the one that, in all of the cell
lines, resulted in the higher numbers of parameters that were significantly different from
the control.
CMT-28 concentrations 1 and 2 resulted in a significantly higher maximum
percentage of maximum aggregation (P < 0.05), and all three concentrations resulted in a
significantly higher slope (P < 0.05), but none of the concentrations resulted in different
AUC values. All three concentrations of OSCA-8 resulted in significantly higher
maximum aggregation percentage and slope (P < 0.05), and only concentration 2 resulted
in a significantly higher AUC (P < 0.05). All three OSCA-40 concentrations resulted in
higher maximum aggregation percentages and AUC (P <0.01), and only concentration 2
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had a significantly higher slope (P < 0.001). All three concentrations of OSCA-78
resulted in higher maximum aggregation percentages (P < 0.05) and slope (P < 0.001),
and none of the concentrations resulted in different AUCs.
We tested whether pre-incubation with the ADP receptor P2Y12 antagonist would
interfere with the aggregation of platelets induced by concentration 2 of cancer cells (1
cell/100 platelets). Platelet maximum aggregation percentage and slope induced by all the
four cancer cell lines were significantly inhibited when the PRP was pre-treated with the
receptor antagonist (Fig. 3.4). AUC was not altered by the receptor antagonists in any of
the cell treatments.
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Figure 3.2

Light transmittance aggregometry parameters of canine platelets activated
by cancer cell lines in three different concentrations.

Canine osteosarcoma (OSCA-8, OSCA-40, and OSCA-78) and mammary carcinoma
(CMT-28) cell lines were added to heparinized platelet rich plasma and aggregation
parameters were measured by light transmittance aggregometry (n = 4-8). Bars represent
average percent maximum aggregation, slope and area under the curve (AUC), with
standard deviation of the means. *indicates significantly different (P < 0.05) from
concentration 1. **indicates significantly different (P < 0.05) from concentration 2.
Concentrations: 1, 1 cancer cell/200 platelets; 2, 1/100; 3, 1/66.
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Figure 3.3

Light transmittance aggregometry parameters of canine platelets activated
by four different cancer cell lines

Canine osteosarcoma (OSCA-8, OSCA-40, and OSCA-78) and mammary carcinoma
(CMT-28) cell lines were added to heparinized platelet rich plasma (1 cancer cell for
every 200 platelets) and aggregation parameters were measured by light transmittance
aggregometry (n = 4-6). Bars represent average percent maximum aggregation, slope and
area under the curve (AUC), with standard deviation of the means. * indicates
statistically significant differences (P < 0.05) from autologous peripheral blood
mononuclear cells (control).
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Figure 3.4

Effect of preincubation with an ADP inhibitor in the percent maximum
aggregation of canine platelets by cancer cell lines

Canine osteosarcoma (OSCA-8, OSCA-40, and OSCA-78) and mammary carcinoma
(CMT-28) cell lines were added to heparinized platelet rich plasma in a ratio of 1 cell per
each 100 platelets, after incubation with 160 μM P2Y12 ADP receptor inhibitor (PSB
0739), and maximum percent aggregation was measured by light transmittance
aggregometry (n = 3-5). Bars represent average percent aggregation with standard
deviation of the means. * indicates statistically significant differences (P < 0.05) from
pre-incubation with diluent (control).
3.4

Discussion
The main objective of this study was to evaluate whether canine cancer cells

would activate platelets in vitro. Light transmission aggregometry measures luminosity as
aggregation occurs in agonist-stimulated PRP and is considered the current gold standard
of platelet function assessment (Michelson, 2004; Paniccia et al., 2015). Agonists such as
ADP, collagen, and AA are well known and commonly used as aggregating agents
(Defontis et al., 2013). However, standard protocols for canine platelet aggregation in
response to different agonists using this technique are not widely available in the
literature. Moreover, the assay needs standardization for its use in each individual
laboratory. Therefore, a significant part of this project was dedicated to the establishment
of protocols for canine platelet aggregation to several agonists. These included
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optimization of blood collection and platelet preparation protocols as well as the
determination of the aggregation response pattern of canine PRP to activation by several
agonists. The outcomes from this first set of experiments were essential for the major
portion of this study, for two reasons. Firstly, the optimization of sample preparation and
use of controls ensured that the data acquired from the cancer cell activation experiments
was reliable. Secondly, we needed to test the receptor antagonists that we would be used
in the second part of the study.
In the experiments described here, ADP resulted in a dose-dependent aggregation
response that was consistently observed in all tested samples. Aggregation was reversible
at low concentrations, but irreversible when 10 μM or more was used. This pattern of
response is in agreement to what was previously reported for canine platelet aggregation
by ADP (Clemmons & Meyers, 1984; Nielsen et al., 2007).
The recommended concentration of ADP for inducing aggregation in human PRP
is 5 μM, which results in a biphasic curve. Concentrations lower than 1 μM induce
reversible primary aggregation (Chrono-logCorporation, 2015). In our settings, we
observed that at least 10 μM of ADP is needed to induce non-reversible aggregation in
canine PRP samples. Our results are in accordance with several other studies utilizing
canine platelet aggregometry. While variable ADP-induced platelet aggregation has been
described in several studies using either canine PRP (Clemmons & Meyers, 1984) and
whole blood (Jackson et al., 1985), many other studies have reported that 10–20 μM of
ADP produces the most consistent measurable aggregation (Kalbantner et al., 2010;
Nielsen et al., 2007; Sato & Harasaki, 2002; Soloviev et al., 1999).
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Canine PRP aggregated in response to collagen in an all-or-nothing pattern. The
threshold for achieving aggregation was 10 μg/ml of collagen, and collagen
concentrations higher than that caused little change in the maximum aggregation
percentage. Our optimal collagen concentration of 20.7 μg/ml was much higher that the
concentration recommended by the manufacturer of 1-5 μg/ml for use in human samples
(Chrono-logCorporation, 2015). Some previous canine studies have also reported higher
optimal collagen agonist concentrations (Kalbantner et al., 2010). However, other studies
in dogs used a significantly lower collagen concentration (1 μg/mL) (Sato & Harasaki,
2002; Soloviev et al., 1999).
Gamma-thrombin is derived from proteolytic cleavage of thrombin and has
markedly reduced fibrinogen cleavage activity, which in turn does not result in fibrin
polymerization and sample clotting (HaematologicTechnologies, 2016). Here we used
this thrombin derivative in order to assess the effects of thrombin on platelet aggregation
in PRP. Similar to the collagen aggregation response, gamma-thrombin also induced allor-nothing platelet aggregation.
Neither PAR-activating peptides nor PAR antagonists worked in our setting.
There is very little information on the PARs that participate in canine thrombin-induced
platelet activation. One study reports the successful use of a PAR-4 activating peptide to
activate canine platelets in a flow chamber-based platelet adhesion assay (Ferkau et al.,
2013), however, there are no details on the reagent used. While cDNA sequences suggest
that canine platelets do possess PAR-1, PAR-3, and PAR-4 receptors with similar
sequences to human or mouse platelet receptors (Boudreaux et al., 2007), other studies
have failed to demonstrate activation of canine platelets by agonists of these receptors, in
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accordance with our results in this report. Researchers have been unsuccessful at
stimulating platelet aggregation in whole blood, as measured by changes in electrical
impedance, with PAR-1 (Kalbantner et al., 2010) and PAR-4 (Defontis et al., 2013)
agonists. Moreover, the PAR-1 activating peptide has been shown to be unable to induce
aggregation or intracellular calcium responses in canine platelets (Derian et al., 1995).
In order to test the aggregation properties of TXA2 receptor signaling in canine
PRP, we used both a synthetic analog of the endoperoxide prostaglandin PGH2 that acts
as a TXA2 receptor agonist (U46619) and AA. Although platelet shape change was
observed at several concentrations with both of these reagents, aggregation was only
observed when 4 mM of U46619 and 8 mM of AA were used. These concentrations were
not feasible to be used in multiple samples, due to the low concentration of the
commercially available stock reagents. The recommended concentrations of AA are 0.5
to 1 mM for aggregation of human PRP. In our canine PRP samples, we needed more
than 8 times this amount to stimulate some degree of platelet aggregation. Several
previous studies have also reported weak or absent platelet aggregation responses to AA
and U46619 in dogs. Although these two reagents failed to induce canine platelet
aggregation they consistently resulted in detectable platelet shape change on
aggregometry. These reagents appear to act synergistically and to potentiate ADP and
epinephrine-induced aggregation (Bush & Smith, 1986; Harris et al., 1981; Johnson et
al., 1979; Soslau et al., 1993). Interestingly, variable inter-individual responses to AA
have been demonstrated in dogs (Defontis et al., 2013; Johnson et al., 1979).
Responsiveness has been shown to vary among breeds (Clemmons & Meyers, 1984) and
with age (Clemmons et al., 1985). However, there is at least one report of successful
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canine platelet aggregation in response to AA (Soloviev et al., 1999). Thus, TXA2
receptor binding seems to induce a weak and inconsistent canine platelet response, with
effects varying widely with individual animals and dosages.
After the optimization phase, we tested if canine cancer cells could activate
platelets. The results shown here confirm our hypothesis that canine cancer cells are
capable of activating canine platelets, resulting in platelet aggregation as measured by
light transmittance. Compared to controls, at least one of the three concentrations of each
of the four cell lines utilized resulted in significantly increased percent aggregation and
slope when added to platelets.
In the early 1970’s, a groundbreaking study from Gasic and collaborators (Gasic
et al., 1973) evaluated 32 murine and human cancer cell lines for their ability to stimulate
aggregation of mouse platelets. This group also hypothesized, for the first time, that
thrombocytopenia would result in less metastasis in mice. Their study revealed that
cancer cells vary with regard to their platelet-aggregating properties. Of the cell lines
tested, four out of nine mammary carcinomas, nine out of 16 sarcomas, and one of two
melanomas were able to aggregate platelets in vitro. None of the lymphoma,
plasmacytoma, or leukemia cell lines evaluated showed an ability to stimulate platelet
aggregation. Their study also showed that the cancer cells that aggregated platelets were
more metastatic, the metastatic foci more concentrated in the lung, and that cancer spread
was highly inhibited by thrombocytopenia. Cells that did not aggregate platelets had
fewer metastatic foci, distributed throughout the body (Gasic et al., 1973). Subsequent to
this first report using murine platelets, various cell lines from different cancers have been
shown to aggregate platelets from both laboratory animals and humans. For instance,
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mouse renal adenocarcinoma and neuroblastoma cell lines have been shown to aggregate
mouse and rabbit PRP using light transmittance aggregometry (Hara et al., 1980).
Another study from the same year showed that cell surface proteins extracted from
cultured rat renal sarcoma cells could aggregate rabbit platelets (Pearlstein et al., 1980).
Then, in one of the first experiments utilizing human platelets, adenocarcinoma,
neuroblastoma, melanoma, and mesothelioma cell lines were all shown to be capable of
aggregating human platelets using light transmittance aggregometry (Bastida et al.,
1982). Additionally, human osteogenic sarcoma cell lines were shown to induce human
platelet aggregation either by themselves or after preincubation of the platelets with
epinephrine. In addition, as seen in the mouse studies, this study also demonstrated that
leukemia and lymphoma cells were not able to aggregate human platelets (Mehta et al.,
1987). Many other studies have also demonstrated human platelet aggregation by a
variety of cancer cell lines. Those include several carcinoma cells isolated from patients
(Grignani et al., 1988), human metastatic urinary carcinoma cells and murine B16
melanoma cells (Grignani & Jamieson, 1988), human colorectal adenocarcinoma
(Pearlstein et al., 1981; Radomski et al., 1991), and human osteosarcoma cell lines
(Clezardin et al., 1991).
As was originally described in 1973 (Gasic et al., 1973), other studies have also
found a correlation between the platelet aggregating capability of cancer cell line with its
metastatic potential (Pearlstein et al., 1981; Pearlstein et al., 1980; Radomski et al.,
1991). However, this correlation was not observed with melanoma cell lines (Grignani &
Jamieson, 1988).
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The interaction between cancer cells and platelets, and the resultant platelet
aggregation appear to result from several distinct mechanisms that vary between cell
types. For example, while platelet aggregation by human colon adenocarcinoma,
anaplastic mouse cancer cells (Pearlstein et al., 1981; Radomski et al., 1991) and
mesothelioma cells (Bastida et al., 1982) has been shown to be thrombin-dependent,
many other cancer cell lines have been shown to not depend on thrombin to aggregate
platelets (Bastida et al., 1982; Clezardin et al., 1991; Grignani & Jamieson, 1988).
Similarly, ADP dependence has also been shown to vary between cancer cell lines. Some
cell lines induce platelet aggregation that is then inhibited by the addition of apyrase, a
compound that breaks down ADP (Bastida et al., 1982; Grignani & Jamieson, 1988). In
contrast, in other cell lines, the absence of ADP does not inhibit platelet aggregation
activity (Bastida et al., 1982; Clezardin et al., 1991). In our experiments, blockage of an
ADP receptor on canine platelets significantly inhibited aggregation induced by the
cancer cells, suggesting that ADP binding is important for the mechanism of platelet
aggregation by these cell lines.
Other mechanisms of cancer cell line stimulation of platelet aggregation involve
platelet and/or cancer cell membrane-associated molecules. Platelet receptor glycoprotein
(GP) IIb-IIIa and its ligands fibronectin and vWF, and also GPIb, have been
demonstrated to affect platelet-cancer cell interactions (Clezardin et al., 1993; Nierodzik
et al., 1995). Similarly, cancer cell trypsinization and treatment with phospholipase A2 or
non-ionic detergents have been shown to inhibit their platelet aggregating ability
(Clezardin et al., 1991; Hara et al., 1980). Finally, other than membrane proteins, the
degree of cell surface sialylation has also been shown to affect cancer cell-induced
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platelet aggregation in a rat sarcoma model (Pearlstein et al., 1980). In our experiments,
pilot studies revealed that trypsinized osteosarcoma cells were also capable of
aggregating platelets (data not shown). However, we decided to use the citric saline
method of harvesting adherent cells throughout the whole study, in order to avoid a
possible effect of trypsin on the activation properties of the cancer cells.
Another protein that seems to have an important role in platelet activation by
cancer cells is thrombospondin. The ability of human OSCA (Clezardin et al., 1991) and
melanoma (Boukerche et al., 1995) cell lines to aggregate platelets have been shown to
be dependent on this protein.
Lastly, it is worth mentioning that in the vast majority of previously reported
studies, platelet aggregation properties of cancer cells were evaluated in samples
collected in heparin. Early studies demonstrated that cancer cell-induced platelet
aggregation would not occur in the presence of citrate (Bastida et al., 1982; Grignani &
Jamieson, 1988; Hara et al., 1980). Since citrate is a chelating agent, it will decrease the
availability of divalent cations, such as magnesium, which has been shown to be required
for platelet aggregation induced by cancer cells (Hara et al., 1980). In accordance with
these previous reports, we used heparinized PRP in our experiments. In pilot studies, we
also observed a lack of cancer cell-induced platelet aggregation when the blood sample
was collected in sodium citrate (data not shown).
Our study demonstrates that the platelet ADP receptor P2Y12 is important for the
canine platelet aggregation induced by the cancer cells utilized. This receptor is
considered the major platelet ADP receptor, mediating full platelet aggregation responses
through inhibition of adenylcyclase and stabilization of platelet aggregates. The P2Y12
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receptor also promotes platelet granule release, thromboxane generation, and expression
of pro-coagulant activity (Storey et al., 2000; Zhou & Schmaier, 2005). Engagement of
the P2Y12 receptor is also required for amplification of platelet activation induced by
ADP and low concentrations of other platelet agonists, including TXA2, collagen, and
thrombin (Boudreaux & Catalfamo, 2010). Indeed, in our study, the blockage of this
receptor also diminished collagen-induced aggregation. However, the magnitude of the
decrease in percent maximum aggregation induced by collagen when pre-incubated with
the P2Y12 antagonist was lower (20% decreased) than what was observed when
aggregation was induced by the cancer cells (56% decreased), on average.
As described previously, and as demonstrated in this study, cancer cells can
definitely affect platelets in vitro. Furthermore, both human and animal model research
also clearly demonstrates an important link between cancer and hemostasis in vivo. The
prothrombotic or hypercoagulable state that frequently affects cancer patients results
from a variety of different mechanisms, including the activation of various hemostatic
components, such as the coagulation and fibrinolytic pathways, the vascular endothelium,
monocytes, and platelets (Caine et al., 2002). The role of platelets in this prothrombotic
state is emphasized by the fact that patients with advanced cancer can have increased
platelet activation, increased platelet turnover, and decreased platelet survival time
(Blann et al., 2001; Scialla et al., 1979). In dogs, detailed information about this type of
interaction between cancer and platelets is still lacking.
In conclusion, in the first part of our study, we showed that although canine
platelets adequately respond to most agonists tested, the agonist concentrations needed
are higher than what has been reported for humans. Additionally, PAR agonists or
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antagonists do not appear to affect canine platelet aggregation at the tested
concentrations. Then, in the second part of our study, we demonstrated that, similarly to
what has been observed in human and murine cancer cell experiments, canine cancer
cells can aggregate platelets in vitro. Aggregation appears to involve the ADP receptor
P2Y12, at least for the cancer cell lines evaluated in our study. Therefore, it is likely that,
in dogs, as in other species, cancer can also activate platelets in vivo.
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CHAPTER IV
PLATELETS INHIBIT MIGRATION OF CANINE CANCER CELLS

Part of the content of this chapter was accepted for publication: Bulla SC, Badial
PR, Silva RC, Lunsford K, Bulla C. (in press). Canine platelets inhibit osteosarcoma cell
migration. Journal of Comparative Pathology.
4.1

Introduction
The interaction between platelets and tumor cells has long been recognized as

important for tumor survival, progression, and metastasis. In human and murine tumor
cell lines, thrombocytopenia, antiplatelet treatment, or blockade of platelet adhesive
proteins such as P-selectin, glycoprotein (GP) Ib-IX, and GPIIb-IIIa, have been shown to
hinder cancer metastasis (Garcia et al., 2007; Jain et al., 2007; Pearlstein et al., 1984;
Trikha et al., 2002), revealing important roles for platelets in tumor progression. Recent
studies have suggested that the direct signaling between platelets and epithelial cancers
facilitates the metastasis of such tumors (Labelle et al., 2011, 2014; Schumacher et al.,
2013).
Several spontaneously occurring canine tumors exhibit very similar behavior to
that of comparable human cancers. For this reason, dogs bearing naturally-occurring
cancer have been proposed as appropriate models for studying cancer biology, assessing
therapeutic targets, and evaluating the diagnostic value of platelet-associated biomarkers
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for predicting and following cancer progression. As dogs routinely share the same
environment as humans and have a naturally shorter life span, the use of this species to
study cancer progression holds several advantages. In addition, cancer is a leading cause
of death in owned dogs in the United States, and there is a shared demand for the
development of new diagnostic techniques and therapies, making clinical trials in canine
patients with spontaneous tumors a useful addition to the therapeutic development
pipeline (Rowell et al., 2011).
Since the role of platelets in cancer growth and spread in dogs remains
undetermined, there is an imperative need for research in this field. Thus, as an attempt to
better characterize the effect of platelets on tumor development in the dog, the objective
of this study was to test whether canine platelets or their contents affect in vitro migratory
behavior in canine osteosarcoma and mammary carcinoma cell lines.
4.2
4.2.1

Material and methods
Experimental design
For the experiments described here, we used three canine osteosarcoma cell lines

(OSCA-8, OSCA-40, and OSCA-78) and a canine mammary carcinoma cell line (CMT28) that were previously established from dogs with spontaneously occurring
osteosarcoma and mammary carcinoma, respectively (Scott et al., 2011; Wolfe et al.,
1986). Platelets and leukocytes used for the cell treatments were isolated from the whole
blood of healthy, young adult, female, Treeing Walker Coonhound dogs. This study was
done in two sets of experiments: the first set was done with the three OSCA cell lines,
and the second evaluated the mammary carcinoma cell line.
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Cancer cells were subjected to four different treatments: intact platelets, intact
platelets and leukocytes, platelet lysates, and platelet releasates. Platelet lysate samples
were supernatants of platelets treated by sonication. Platelet releasates were the
supernatants of platelets activated by thrombin. Treatments consisted of either 107 intact
platelets or equivalent volumes of platelet releasate, lysate, or controls, added to 105
cancer cells (a ratio of 100 platelets for each cancer cell). For the platelet plus leukocyte
treatments, 106 leukocytes were also added to the tumor cells with intact platelets (10
leukocytes for each tumor cell).
The effect of the different treatments on the migratory behavior of the
osteosarcoma and mammary carcinoma cell lines was measured using an in vitro
migration assay. The a priori sample size was calculated by power analysis using effect
size ≥ 1.5 (these effect sizes were observed either in pilot experiments performed in our
laboratory or previously published studies), type I error probability of 0.05, and desired
power of 0.8.
4.2.2

Blood collection
Venipunctures were performed with minimal trauma on the jugular vein using a

20-gauge needle directly either into a syringe containing 3.2% sodium citrate or a
vacutainer tube containing 5% EDTA for platelet and leukocyte preparations,
respectively. Blood draws and sample handling were performed with care in order to
avoid in vitro platelet activation.
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4.2.3

Platelet and leukocyte sample preparation
In the first set of experiments (with OSCA cell lines), purified platelet isolation

was performed using the protocol described previously by our laboratory (Trichler et al.,
2013), with modifications. Briefly, platelet rich plasma (PRP) was obtained by whole
blood centrifugation at 1,200 × g for 3 min. The whole plasma was collected and
subjected to centrifugation on a 1.063 g/ml iodixanol density barrier (OptiPrepTM, SigmaAldrich®, St. Louis, MO, USA), at 350 × g, for 15 minutes, at 20 ºC, with no brake. One
milliliter of the interface cloudy layer, which consisted of the purified platelet sample,
was aspirated. For the mammary carcinoma cell line experiments, washed platelets were
prepared for the treatments. Whole blood was spun at 300 × g, for 5 min, with no brake
applied. The upper two-thirds of plasma were aspirated, and the centrifugation procedure
was repeated 2-3 times. PRP collected in all centrifugation steps was combined, and
platelets were washed once and resuspended in phosphate buffered saline (PBS). For all
samples, a hemocytometer was used to manually count platelets and leukocytes. Both
protocols were demonstrated in our laboratory to not cause platelet activation, by light
microscopy morphology, Annexin V binding and flow cytometry, or activation response
to agonists in aggregometry studies (data not shown).
To prepare platelet fractions, platelets were either activated using thrombin
(Chrono-log Corporation, Havertown, PA, USA) for 10 minutes at room temperature, or
lysed by ultrasonication with 10 bursts of 5 seconds each at intervals of 60 seconds and at
50% amplitude (Q125 Sonicator, QSonica LLC, Newtown, CT, USA). Then, releasates
(from thrombin-activated samples) and lysates (from sonicated samples) were collected
after centrifugation at 10,000 × g, for 10 minutes, at 4 ºC. Leukocyte isolation was
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performed using a density centrifugation protocol previously described (Strasser et al.,
1998). Final isolated leukocytes were resuspended in PBS. The sample was examined for
leukocyte and platelet numbers on a hemocytometer. Leukocyte viability was assessed
using the trypan blue (Life TechnologiesTM, Grand Island, NY, USA) exclusion method.
4.2.4

Cell culture
Cells were maintained in Dulbecco’s Modified Eagle’s Medium containing 5%

glucose, and supplemented with 10% fetal bovine serum (FBS) (Gibco®, Grand Island,
NY, USA), 0.1 mg/ml PrimocinTM (InvivoGen, San Diego, CA, USA), and 10 mM
HEPES buffer solution (Sigma-Aldrich®, St Louis, MO, USA). The cells were seeded in
T75 flasks and incubated in a CO2 incubator at 37°C, 5% CO2 level (Thermo Scientific,
Waltham, MA, USA) and were split when they reached 80% confluence.
4.2.5

Migration assay
Transwell migration assays were performed using 24-well plate culture inserts

with 8 µm pores (Corning® Costar Corporation, Cambridge, MA, USA). Tumor cells
were starved for 16 to 24 hours in medium containing 0.5% FBS prior to the experiments.
For the experiments, 105 cells were suspended in medium containing 0.5% FBS and coincubated with each treatment and appropriate controls in the upper chamber of each
transwell. Medium containing 10% FBS was used as a chemoattractant in the lower
chamber. Cells were incubated with treatments for 16 (OSCA experiments) or 24 (CMT28 experiments) hours.
In the OSCA cell line experiments, by the end of the incubation time, cells were
fixed using 3.7% paraformaldehyde (Electron Microscopy Sciences, Hatfield, PA, USA),
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permeabilized with methanol, and Giemsa stained (Sigma-Aldrich®, St Louis, MO,
USA). Cells from the upper surface of the membrane were removed with a sterile cotton
swab (Puritan®, Guilford, ME, USA). The cells attached to the lower surface of the
membrane were counted under inverted microscopy (Olympus IX50, Olympus®,
Bethlehem, PA, USA), and the average of cells per field at 400x magnification was
obtained.
In the CMT-28 experiments, cells that migrated to the lower surface of the
membrane were counted by flow cytometry, with the use of broadly fluorescent
microspheres (CountBright absolute counting beads, Molecular Probes, Eugene, OR).
Detection and counting of cells and beads were done in an FACSCalibur flow cytometer
with Cell Quest software (BD Biosciences, San Jose, CA, USA). After the incubation
time, media from the transwells was discarded and the cells that migrated to the lower
side of the membrane were detached by incubation with trypsin/EDTA for 5 minutes.
After addition of media with 10% FBS, cells were pelleted and resuspended in PBSsodium azide buffer containing the counting beads. Flow cytometry was performed
immediately, following manufacturer’s instructions.
4.2.6

Data analysis
Data are presented as mean with standard errors of the means. A generalized

linear model (PROC GLM; SAS 9.4®; SAS Institute Inc., Cary, NC, USA) was
constructed to compare the mean number of cells per high power field or total migrated
cells between treatments. Tukey’s test was used to adjust the P values resulting from
multiple comparisons. The possible variation among replicates was included in the
models. All analyses were conducted using a level of significance of 0.05.
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4.3
4.3.1

Results
Platelets inhibit migration of canine osteosarcoma and mammary
carcinoma cell lines
The intact purified platelets significantly (P < 0.001) decreased the migration of

all studied OSA cell lines as compared to the untreated cells (Fig. 4.1). Similarly,
migration of CMT-28 was decreased (P < 0.001) by intact washed platelets (Fig. 4.2).
These results indicate that healthy canine platelets inhibit the migration of these canine
tumor cells.
4.3.2

Platelet effect on tumor cell migration is not impeded by leukocytes
In all three OSA cell lines, significant (P ≤ 0.001) inhibition of migration was

observed for both purified platelets and leukocyte-contaminated platelets when compared
to the control, with no significant difference between treatment groups (Fig. 4.1). These
results suggest that the presence of a large number of leukocytes does not alter the
platelet effect, and migration remains impaired in the studied osteosarcoma cells.
Interestingly, in the CMT-28 cell line, the addition of leukocytes to the purified platelets
actually resulted in significantly (P < 0.001) lower numbers of migrated cells compared
to the washed platelets only (Fig. 4.2).
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Figure 4.1

Effect of platelets and platelets plus leukocytes on the in vitro migration of
canine osteosarcoma cell lines

The cell lines OSCA-8 (n = 12), OSCA-40 (n = 12), and OSCA-78 (n = 3) were coincubated with purified platelets (platelets), leukocyte-contaminated platelets (platelets +
WBC), or iodixanol density barrier (control), for 16 hours. Bars represent the average
number of cells per high power field (hpf) with standard deviation of the means. Means
with different letters indicate statistically significant differences between groups (Tukey’s
test, P ≤ 0.05).
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Figure 4.2

Effect of platelets and platelets plus leukocytes on the in vitro migration of
a canine mammary carcinoma cell line

Canine mammary carcinoma cell line CMT-28 was co-incubated with purified washed
platelets (platelets, n = 36), leukocyte-contaminated platelets (platelets + WBC, n = 12),
or phosphate buffered saline (control, n = 34) for 24 hours. Bars represent the average
number of cells that migrated through the transwells with standard deviation of the
means. Means with different letters indicate statistically significant differences between
groups (Tukey’s test, P ≤ 0.05).
4.3.3

Platelet lysate and releasate impair tumor cell migration
Platelet lysate significantly inhibited the migration of all three osteosarcoma cell

lines (P ≤ 0.001) at a magnitude similar to the intact platelets. The thrombin-activated
platelet releasate also significantly impaired osteosarcoma cell migration to a similar
magnitude in two of the cell lines, OSCA-8 and OSCA-40 (P ≤ 0.001), and although the
migration of OSCA-78 cells was impaired, the decrease in migration was not statistically
significant (P = 0.15) (Fig. 4.3).
For the CMT-28 cells, platelet lysates did not result in a significant inhibition of
migration. In contrast, thrombin-activated platelet releasate significantly (P < 0.001)
inhibited migration, at a similar magnitude as intact washed platelets (Fig. 4.4).
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Figure 4.3

Effect of intact platelets, platelet lysate, and platelet releasate on the in
vitro migration of canine osteosarcoma cell lines

The cell lines OSCA-8 (n = 12), OSCA-40 (n = 12), and OSCA-78 (n = 3) were coincubated with intact purified platelets (platelets), platelet lysate (lysate), 1U/ml
thrombin-activated platelet releasate (releasate), iodixanol density barrier (control, left),
or iodixanol density barrier plus 1 U/ml thrombin (control, right), for 16 hours. Bars
represent the average number of cells per high power field (hpf) with standard deviation
of the means. Means with different letters indicate statistically significant differences
between groups (Tukey’s test, P ≤ 0.05).
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Figure 4.4

Effect of intact platelets, platelet lysate, and platelet releasate on the in
vitro migration of a canine mammary carcinoma cell line.

Canine mammary carcinoma cell line CMT-28 was co-incubated with intact washed
purified platelets (platelets, n = 36), platelet lysate (lysate, n = 12), 20 mM gamma
thrombin-activated platelet releasate (releasate, n = 12), phosphate buffered saline
(control, left, n = 32), or phosphate buffered saline plus 20 mM gamma-thrombin
(control, right, n = 12) for 24 hours. Bars represent the average number of cells that
migrated through the transwells with standard deviation of the means. Means with
different letters indicate statistically significant differences between groups (Tukey’s test,
P ≤ 0.05).
4.4

Discussion
Canine platelets and molecules that are produced and/or stored and released by

platelets inhibit in vitro migration of osteosarcoma and mammary carcinoma cell lines.
The effect, however, was reduced in OSCA-78 cells when compared to the treated
OSCA-8 and OSCA-40 cell lines, which suggests that the magnitude of the effect of
platelets on tumor cells varies within tumor cell lines. In the CMT-28 studies, the
reduction in migration was less pronounced than what was observed with the OSCA cell
lines. However, the platelet sample preparation utilized was different for the mammary
carcinoma cell line experiments, where we used purified washed platelets. This extra step
in the protocol ensured that, as well as being purified from leukocytes and erythrocytes,
these samples were also free of residual plasma products that might have been present in
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the samples for the first set of experiments and could have been a source of confounding
data.
Nonetheless, our results clearly suggest that canine platelets have an inhibitory
effect on the migration of tumor cells. This finding is in contradiction to the consensus of
the literature to date, which has shown that platelets have a positive effect on the
migration of tumors. For human and murine tumor cells, there is substantial evidence that
platelet treatment promotes tumor cell survival and increases metastatic cell seeding
(Labelle et al., 2011, 2014; Schumacher et al., 2013). In addition, both induced
thrombocytopenia and antiplatelet therapy have repeatedly been shown to inhibit the
development of metastasis in several tumor types (Gasic et al., 1973; Gasic et al., 1968;
Labelle et al., 2011). The hypothesis that platelets have a positive overall impact on
cancer progression is feasible since platelets are thought to play a role in several different
steps in cancer growth and metastasis. For example, platelets may aid in tumor cell
survival in the bloodstream through the formation of a physical shield that protects from
natural killer-mediated lysis (Palumbo et al., 2005). In addition, platelets limit blood flow
shear-induced damage to tumor cells (Egan et al., 2014), and facilitate the adhesion of
tumor cells to the endothelium (Im et al., 2004). They may also facilitate tumor cell
extravasation at metastatic sites since they have been shown to stimulate trans-endothelial
migration of tumor cells in vitro (Schumacher et al., 2013). Finally, it has been observed
that epithelial tumor cells transform into a more mesenchymal, more mobile, phenotype
after platelet treatment. This is characterized by increased expression of epithelial to
mesenchymal transition-associated genes and matrix metallopeptidase 9 secretion, both
associated with more invasive and metastatic behavior (Labelle et al., 2011).
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Our results show a reduction in migratory behavior in canine osteosarcoma and
mammary carcinoma cell lines following platelet treatment, a finding that differs
markedly from observations in similar studies using murine and human cancer cells. To
the best of our knowledge, there are no reports on the effect of platelets on canine tumor
cell lines or cancer in dogs, therefore canine platelets and tumor cells may interact
differently than in other species. Nearly all studies in other species used melanomas or
tumor cells of epithelial origin (i.e., carcinomas). There is very little information
regarding the effect of platelets on the migratory or metastatic behavior of mesenchymal
tumors in any species. The only exception is a study in mice that reported that induced
thrombocytopenia resulted in decreased lung metastasis of fibrosarcoma cells, indicating
that mouse platelets might have a positive effect on the spread of sarcomas (Gasic et al.,
1973). Our results show that, in dogs, platelets inhibit migration of both sarcoma and
carcinoma cell lines.
In order to evaluate whether contamination of platelet samples with blood
leukocytes would impact our results, we treated tumor cells with platelets plus
leukocytes. While our platelet only samples had an average of one leukocyte per each
65,939 platelets (range 1/6,136 – 1/130,250), the platelet plus leukocyte samples had one
leukocyte per each 10 platelets, which is equivalent to twice as many as typically
reported in canine PRP (Franklin et al., 2015). Thus, these contaminated samples had on
average more than 6,000-fold the number of leukocytes than the purified platelet samples.
Since these leukocyte-contaminated platelet samples had the same inhibitory effect on
osteosarcoma cells migration, the osteosarcoma cell migratory behavior was not
significantly impacted by the presence of the added leukocytes. Therefore, it seems that
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leukocytes do not interfere with the platelet effect on these cells. In CMT-28, in contrast,
the addition of leukocytes to the purified platelets resulted in even lower numbers of
migrated cells compared to the washed platelets, which indicates that leukocytes also
inhibit migration of these mammary carcinoma cells, amplifying the effect of platelets.
The effect of blood leukocytes on the migration of carcinoma cells would be an
interesting topic for further study, although it is out of the scope of the present discussion.
The mechanisms by which platelets alter tumor cell behavior in humans and mice
are not fully understood, although evidence suggests that it involves both direct platelettumor cell contact and platelet-released molecules. It has been demonstrated that platelets
promote migration and metastasis of epithelial-origin cancers through the synergistic
effect of platelet-tumor cell direct contact and platelet-derived TGFβ signaling (Labelle et
al. (2011). Moreover, platelets stimulate the in vitro trans-endothelial migration of murine
skin melanoma and lung carcinoma cells through release of nucleotides from dense
granules (Schumacher et al., 2013), indicating that the contents of these granules might
enhance cancer migration and metastasis in mice. In the present study, platelet lysate and
intact platelets had the same inhibitory effect on migration of all three osteosarcoma cell
lines, indicating that direct platelet-tumor cell contact is not necessary for this effect in
these cells. Platelet releasate was enough to cause inhibition of migration in two of the
osteosarcoma cell lines, indicating that the molecule(s) responsible for the inhibitory
effect of migration is likely derived from platelet granules. However, in the OSCA-78
cells, platelet releasate did not have a statistically significant effect on migration. Since
this cell line had migration inhibited by intact platelets and lysate, showing that platelet
contents do have an effect on its migration, this unexpected result might be attributed to
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the fact that the amount of protein that was released from the activated platelets did not
reach the necessary levels to significantly inhibit the migration of this cell line. For the
CMT-28 cell line, although platelet releasate significantly inhibited cell migration,
similar to the effects of intact washed platelets, lysates did not result in a significant
inhibition of cell migration. This outcome could be explained by the presence of an
unknown confounding factor, found in the lysate but not in releasate, which impeded the
effective molecule(s) present in both lysate and releasate. Alternatively, platelet
activation could have stimulated the expression of molecules not initially present in the
platelets that then inhibited cancer cell migration.
Altogether, the findings of this study suggest that canine platelet content is
sufficient to impact tumor cell migration and that direct platelet-tumor cell contact is not
required. These results also suggest that a molecule (or molecules) that is stored in nonactivated circulating platelets and then released upon thrombin activation is responsible
for the impact on the migration of cell lines. The findings that platelet releasate did not
significantly impair the migration of OSCA-78 cells and that platelet lysate did not
significantly inhibit migration of CMT-28 cells may suggest that these particular cell
lines are less sensitive to the factor or factors involved in the inhibitory effect and/or may
be a result of insufficient sample size.
In conclusion, intact platelets and their contents inhibit migration of canine
osteosarcoma and mammary carcinoma cell lines. This suggests that platelets might
inhibit the migratory phase of cancer metastasis in dogs, impeding cancer spread,
contrary to what is described in humans and mice.
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CHAPTER V
DIFFERENT EFFECTS OF PLATELET RELEASATES ON
MIGRATION OF CANINE CANCER CELLS

5.1

Introduction
Although platelets in mice and humans have long been shown to promote cancer

cell migration and assist in metastasis, the mechanisms of these activities are not fully
understood. Also, platelets were shown to selectively package and release contents
depending on agonist activation (Battinelli et al., 2011; Chatterjee et al., 2011; Italiano et
al., 2008; Sehgal & Storrie, 2007; Villeneuve et al., 2009). There are no similar published
research reports in domestic animals. We have demonstrated that canine platelets
differentially package proteins and other mediators, which supports a potential different
release of these and other proteins contained in alpha granules (Curotto et al., 2012).
However, contrary to the current human and mouse literature, we have found that canine
platelets actually inhibit migration of some cancer cell types in vitro (Bulla et al., in
press). Therefore, we wondered if releasate originating from canine platelet activation by
different agonists differentially affects cancer cell migratory behavior
The objective of the present study was to evaluate if platelets activated by
different agonists would yield different releasates with distinctive properties, and with
this, better characterize the effects on canine platelets in tumor cell migration.
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5.2
5.2.1

Material and methods
Experimental design
In the current experiment, we used three canine osteosarcoma cell lines (OSCA-8,

OSCA-40, and OSCA-78) and one canine mammary carcinoma cell line (CMT-28) that
were previously established from dogs with spontaneously occurring cancers (Scott et al.,
2011; Wolfe et al., 1986). Platelets were isolated from the whole blood of healthy, young
adult, female, Treeing Walker Coonhound dogs. Tumor cells were incubated with intact
washed platelets, equivalent volumes of releasates derived from platelet activation using
three different agonists, or respective controls. The effect of the treatments on the
migratory behavior of the osteosarcoma and mammary carcinoma cell lines was
measured using an in vitro migration assay. The a priori sample size was calculated by
power analysis using an effect size ≥ 1.5 (these effect sizes were observed either in pilot
experiments or previous studies performed in our laboratory), a type I error probability of
0.05, and the desired power of 0.8.
5.2.2

Blood collection
Venipunctures were performed on the jugular vein using a 20-gauge needle and a

10 mL syringe containing 1 mL of 3.2% sodium citrate (Sigma-Aldrich, St. Louis, MO,
USA). Blood was then immediately transferred to a 15 mL conical polypropylene tube
(Corning, Corning, NY, USA). Blood draws and sample handling were carefully
performed in order to avoid in vitro platelet activation.
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5.2.3

Platelet sample preparation
Whole blood was spun at 300 × g for 5-7 minutes, with no break, and the upper

two-thirds of the platelet rich plasma (PRP) were taken. This procedure was repeated
twice or three times, and the PRP obtained from the different centrifugations was
combined. Platelet and leukocyte concentrations were determined manually with a
hemocytometer. For the washed platelet preparations, the PRP was diluted in an
approximately 1:1 ratio with phosphate buffered saline (PBS) to a total volume of 1 mL,
pelleted at 500 × g for 8 minutes, and resuspended in PBS to a concentration of 200,000
platelets per microliter. This protocol has previously been demonstrated in our laboratory
to not cause platelet activation when evaluated by examination of platelet morphology
under light microscopy, and by activation responses to agonists in aggregometry studies.
The agonists and concentrations used for platelet activation were: 20 nM gammathrombin (Haematologic Technologies, Essex Junction, VT, USA), 10 μM adenosine
diphosphate (ADP), and 20.7 μg/ml collagen (ADP and collagen were both from Chronolog Corporation, Havertown, PA, USA). To perform the platelet activation, 250 μl of
washed platelets were incubated with each of the different agonists for 10 minutes at
room temperature. After incubation, samples were spun at 1,000 × g, for 5 minutes, and
the supernatants were collected.
5.2.4

Cell culture
Cells were maintained in Dulbecco’s Modified Eagle’s Medium containing 5%

glucose (Gibco®, Grand Island, NY, USA), supplemented with 10% fetal bovine serum
(FBS) (Gibco®, Grand Island, NY, USA), 0.1 mg/ml PrimocinTM (InvivoGen, San Diego,
CA, USA), and 10 mM HEPES buffer solution (Sigma-Aldrich®, St Louis, MO, USA).
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The cells were seeded in T75 flasks, incubated at 37°C, 5% CO2 (Thermo Scientific,
Waltham, MA, USA), and split when they reached about 80% confluence.
5.2.5

Migration assay
Transwell migration assays were performed using 24-well plate culture inserts

with 8 µm pores (Corning® Costar Corporation, Cambridge, MA, USA). For the
experiments, 1 x 105 cells were suspended in medium containing 0.5% FBS and coincubated with treatments or appropriate controls in the upper chamber of each transwell.
Controls consisted of medium with added PBS containing the respective agonist in the
same concentration used to activate the platelets. Medium containing 10% FBS was used
as a chemoattractant in the lower chamber. Plates were incubated for 24 hours and cells
that migrated to the lower surface of the membrane were counted by flow cytometry,
with the use of broadly fluorescent microspheres (CountBright absolute counting beads,
Molecular Probes, Eugene, OR) to determine cell concentrations. Detection and counting
of cells and beads were done in the FACSCalibur flow cytometer with Cell Quest
software (BD Biosciences, San Jose, CA, USA). After the incubation time, media from
the transwells was discarded and the cells that migrated and were attached to the lower
side of the membrane were detached by incubation with trypsin/EDTA for 5 minutes.
After addition of media with 10% FBS, cells were pelleted and resuspended in PBSsodium azide buffer containing a known fixed number of counting beads. Flow cytometry
was performed immediately after cell resuspension, following the manufacturer’s
instructions.
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5.2.6

Data analysis
Data are presented as mean with standard errors of the means. A generalized

linear model (PROC GLM; SAS 9.4®; SAS Institute Inc., Cary, NC, USA) was
constructed to compare the total migrated cells between treatments. Tukey’s test was
used to adjust the P values resulting from multiple comparisons. The possible variation
among replicates was included in the models. The level of significance was 0.05 in all
analyses.
5.3
5.3.1

Results
Platelets inhibit migration of canine cancer cell lines
As expected based on the basis of our previous results, purified intact washed

platelets significantly decreased cancer cell migration in all cell lines (P < 0.0001, Fig.
5.1 and 5.2). For the CMT-28 and OSCA-78 lines, platelet treatment resulted in a 25%
decrease in cell migration. For the OSCA-8 and OSCA-40 lines, platelet-induced
inhibition of cell migration was even more pronounced, and the number of migrating
cells in the platelet-treated groups was half as much as comparable controls (50%
decrease).
5.3.2

ADP and collagen alone inhibited canine cancer cell migration
For all osteosarcoma cell lines, the addition of ADP in the medium significantly

(P < 0.01) inhibited migration when compared to medium plus PBS only groups. With
the CMT-28 cell line, ADP did not affect cell migration. The presence of collagen in the
top chamber also significantly decreased (P < 0.0001) the number of migrated cells in all
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of the four cell lines. The addition of thrombin in the medium of the top chamber did not
affect migration in any of the cell lines, compared to their respective PBS controls.
5.3.3

Platelet releasates derived from ADP and thrombin activation are
functionally different from collagen-stimulated releasates
ADP-activated platelet releasates induced a decrease in migration of OSCA-8 and

OSCA-40 cells when compared to their controls (PBS + ADP). However, the magnitude
of this inhibition (22% decrease) was smaller than the inhibition observed in the intact
platelet-treated groups (50%). For the CMT-28 and OSCA-78 cell lines, the ADP
releasate did not have a significant effect on cell migration.
Collagen releasates did not change migration of CMT-28 and OSCA-8 cells when
compared to their controls. However, in the other two cell lines, OSCA-40 and OSCA78, the presence of the collagen releasate in the upper chamber resulted in higher
numbers of migrated cells in the bottom chamber (P < 0.01) than their respective
controls.
Thrombin-activated platelet releasate significantly decreased (P < 0.0001) the
number of migrated cells in all but one cell line (OSCA-78). Although the number of
OSCA-78 cells that migrated when treated with the thrombin releasate was also lower
than the control, it did not reach statistical significance. With the CMT-28 cells, the
magnitude of the decrease in cell migration of the thrombin releasate-treated group was
similar to the decrease in magnitude resulting from treatment with washed intact
platelets. For the OSCA-8 and OSCA-40 lines, the inhibition of cell migration by the
thrombin releasate was less pronounced than the inhibition observed when cells were
treated with intact platelets.
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Figure 5.1

Effect of different platelet releasates on in vitro migration of canine
mammary carcinoma cells.

The cell line CMT-28 was incubated for 24 hours with releasates obtained from platelet
activation with 10 μM ADP, 20.7 μg/ml collagen, 20 nM gamma-thrombin, and
respective controls (n = 12); or intact washed platelets (n = 36) and phosphate buffered
saline (pbs, n = 34) as a control. Bars represent the average number of cells migrated with
standard deviation. *indicates significantly different from the control (Tukey’s test , P ≤
0.05).
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Figure 5.2

Effect of different platelet releasates on in vitro migration of canine
osteosarcoma cell lines.

The cell lines OSCA-8, OSCA-40, and OSCA-78 were incubated for 24 hours with
releasates obtained from platelet activation with 10 μM ADP, 20.7 μg/ml collagen, 20
nM gamma-thrombin, and respective controls (n = 12); or intact washed platelets and
phosphate buffered saline as the control (n = 12). Bars represent the average number of
cells migrated with standard deviation. *indicates significantly different from the control
(Tukey’s test , P ≤ 0.05).
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5.4

Discussion
As expected from our previous studies ((Bulla et al., in press); Chapter Four),

intact platelets decreased migration of all tumor cell lines. In the experiments reported
here, we decided to wash the isolated platelets, which purified platelets from plasma,
eliminating the plasma proteins as confounding factors. Therefore, our results here
further confirm the ability of platelets to inhibit the in vitro migration of these canine
tumor cell lines.
To accurately interpret the effect of platelet releasates, each releasate had its own
control, which consisted of medium with the addition of PBS plus the respective agonist
in the same concentration used to activate the platelets. Although it was not a major
objective of this study, these controls allowed us to detect that both ADP and collagen
significantly inhibit cell migration when added to the top chamber. These results were
unexpected and remain mostly unexplained. Although collagen, along with other
components of the extracellular matrix, is significantly involved in cancer migration and
proliferation, (Lu et al., 2012), information about its contribution as a chemoattractant is
scarce. Published results indicate that this action is likely dependent on the cell type.
Collagen type I has been shown to be a chemoattractant to rat mammary carcinoma cells
and human carcinoma cell lines, whereas one rat carcinoma cell line and one rat
osteosarcoma cell line were not attracted by the collagen (Mundy et al., 1981). Thus, it is
reasonable to believe that the collagen used for our experiments might have exerted
chemoattraction on the tumor cell lines, which caused the cells to remain in the upper
chamber and to migrate less to the lower chamber, resulting in lower numbers of counted
migrated cells. Similarly, it is possible that ADP might have inhibited our tumor cell line
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growth and/or migratory behavior since both ATP and adenosine have been implicated in
directly promoting tumor cell growth (Di Virgilio, 2012).
Our major hypothesis for this current study was that releasates originating from
platelets activated by different agonists would have different effects on tumor cell
migration in vitro. The results presented here support this hypothesis. Overall, releasates
derived from platelet activation with ADP and thrombin inhibited cell migration, which
was the same effect observed with intact platelets. The inhibition was, however, generally
less pronounced with the releasates when compared to the magnitude of inhibition caused
by intact platelets. In contrast, releasate from collagen-activated platelets seemed to result
in the opposite outcome of augmenting tumor cell migration. However, a major
confounding factor that exists, in this case, is that, since platelets release vWF when
activated and this factor is known to bind collagen, we do not know for sure how much
collagen effect remains after the platelets activate and release their content. The releasate
will contain likely some unbound collagen, and the molecules released by platelets that
have the effect on cancer cell migration. Since there was not a decrease in migration, it is
reasonable to believe that those molecules did not have an inhibitory effect. Instead, the
results were the opposite (in two cell lines), and the releasate induced an increase in
migrated cells, demonstrating that the molecules released actually antagonize the effect of
collagen.
The results presented here, therefore, suggest that there is a differential release of
molecules from canine platelets when activated by different agonists, at least when
considering factor(s) that influence cancer cell migration.
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When activated, platelets release a variety of substances, such as cellular adhesion
proteins, chemokines, cytokines, coagulation factors, mitogenic factors, angiogenesis
regulatory proteins, and fibrinolytic agents. The majority of these released proteins come
from the alpha granules, which are the main platelet storage granule (Italiano &
Battinelli, 2009; Ma et al., 2005). The mechanisms of protein packaging within alpha
granules and the proteins released upon platelet activation have been topics of intense
discussion and controversy for several years. Although there are many studies supporting
the notion of selective packaging and release of proteins, the mechanisms involved in
these responses are not clear, and this subject still needs much clarification. Studies on
selective activation have mainly focused on the release of pro- and antiangiogenic
molecules, and there is, therefore, a need for investigation of the whole nature of protein
contents and general function of these platelet releasates.
Human platelet alpha granules have been demonstrated to have differential
packaging and selective release of proteins by many research groups (Battinelli et al.,
2011; Chatterjee et al., 2011; Italiano et al., 2008; Sehgal & Storrie, 2007; Villeneuve et
al., 2009). It is believed that this differential distribution is achieved involving subgroups
of granules and/or functional colocalization of the proteins within the granules. Electron
tomography studies of human platelets have demonstrated morphologically different
alpha-granule subtypes and high spatial segregation of cargo within individual alpha
granules (van Nispen tot Pannerden et al., 2010). These findings are supported by several
other experiments that performed selective activation by specific receptor agonists and
demonstrated a distinct release of proteins. For example, several research groups have
studied the two receptors for thrombin on platelets. When activated through protease112

activated receptors (PAR)-1, platelets are shown to release contents with proangiogenic
potential, such as vascular endothelial cell growth factor (VEGF) and stromal cellderived factor-1α. When platelet PAR-4 is activated, the result is the opposite, with the
release of antiangiogenic factors such as endostatin and platelet factor 4 (PF4) (Chatterjee
et al., 2011; Italiano et al., 2008; Ma et al., 2001; Ma et al., 2005). ADP and thromboxane
A2 (TXA2) have also been demonstrated to selectively stimulate human platelets. ADP
induces a proangiogenic releasate, and TXA2 an antiangiogenic releasate (Battinelli et al.,
2011). These same authors also evaluated the activation of platelets by tumor cells, which
induced a selective proangiogenic releasate. There were increased levels of VEGF,
epidermal growth factor (EGF) and platelet-derived growth factor (PDGF), and the
releasate was able to induce endothelial cell proliferation. None of these results were seen
in tumor cell supernatant alone. In accordance with these results, another study showed
that activation of platelets by ADP caused an increase in soluble VEGF concentrations
with minimal effects on endostatin concentrations (Bambace et al., 2010). Finally,
significant variations in platelet releasate between thrombin and collagen stimulation of
platelets were recently demonstrated using a high-resolution differential proteome
analysis (Velez et al., 2015).
Even though the studies mentioned above suggest that proteins with antagonistic
angiogenic functions are separately packaged in platelets, which would seem a reasonable
explanation for functional differential release, the exact pattern of distribution of the
alpha-granule proteins in platelets is still unresolved. In fact, there are some contradictory
results in the literature. For example, one group of researchers reported a study with pairwise colocalization comparisons of several angiogenic factors and proteins synthesized
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and endocytosed and failed to demonstrate any pattern of distribution (Kamykowski et
al., 2011). The selective release of proteins was questioned as well since platelet releasate
proteome experiment results could not confirm differential release after PAR-1 or PAR-4
stimulation. This lack of differential release was confirmed with ELISA measurements of
beta-thromboglobulin, PF-4, thrombospondin, PDGF-A/B, CCL5, endostatin, CXCL12,
and VEGF (van Holten et al., 2014). This lack of difference, however, was observed
following activation of different thrombin receptors only. So far, there is no published
information that refutes the previously reported results documenting differentially
released proteins following platelet activation by agonists other than PAR receptor
agonists.
In our laboratory, using immunofluorescence, confocal microscopy, and staining
of fibrinogen and von Willebrand factor, we have previously demonstrated that canine
platelets have selective packaging and different alpha-granule subtypes, as shown in mice
and humans (Curotto et al., 2012). This information suggested that canine platelets are
similar in this aspect to human and mice platelets, and supports the possibility that they
could also be selectively activated.
Tumor cells will certainly encounter platelets once they enter the blood
circulation as part of the metastatic process. Additionally, within the primary tumor mass,
where the blood vessel is leaky and has a turbulent, nonlaminar blood flow, platelets are
in close contact to the endothelium and can be more easily activated within these
pathological vessels. This may cause platelet-derived molecules to be released in the
proximity of a growing cancer cell mass, where they may influence proliferation and
migration of the tumor cells, as well as angiogenesis (Buergy et al., 2012). In fact, there
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is a strong body of evidence that mouse and human platelets promote cancer cell
migration and assist in metastasis. Early studies also demonstrated that thrombocytopenia
offers protection from metastasis in a murine carcinoma and that the inhibition of
metastasis is reversed with platelet transfusion (Gasic et al., 1968). Also, murine and
human tumor cell lines inoculated into mice have been shown to have metastasis
inhibited when thrombocytopenia is induced (Gasic et al., 1973). Later studies have
further explored the participation of platelets in cancer development. Anti-platelet
antibody given to mice before tumor cell injection has been shown to consistently
decrease the number and size of lung metastases of carcinomas and melanoma (Pearlstein
et al., 1984). Mice with loss of platelet activation along with the injection of melanoma
and lung carcinoma cell lines also had a major reduction in metastases. It was further
observed that platelet function had a protective effect on tumor cells against natural killer
cell-mediated destruction (Palumbo et al., 2005). Additionally, the absence of platelet
glycoprotein Ib-IX resulted in decreased lung metastases in mice with inoculated
melanoma cells (Jain et al., 2007). It has also been observed that adequate platelet
function has All these studies support the concept that in humans and mice, platelets
intensely participate in cancer development, contributing to the growth and spread of
cancer cells. However, the vast majority of these studies evaluated only or mostly
carcinoma cell lines. There is still very little information on the effect of platelets on
cancer cells of mesenchymal origin. Moreover, other than in laboratory mice, there is a
lack of information about the relationship between platelets and cancer in other animal
species.
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Our laboratory studies canine platelet and cancer cell interactions. As previously
described, we have shown that intact platelets can inhibit cancer cell migration in vitro in
dogs (Bulla et al., in press), contrary to the general consensus in the literature derived
from human and mouse studies. We used a limited range of canine osteosarcoma and
carcinoma cell lines for our studies, and it is therefore not possible to determine if our
results differ from the literature because of the different species evaluated, or because of
the inherent characteristics of our cancer cell lines. In the present study, we used these
three canine osteosarcoma cell lines and one mammary carcinoma cell line to test the
effect of intact platelets and different platelet releasates on the in vitro migration activity
of the cancer cells. Again, canine platelets were shown to inhibit migration of these cells,
and although there were some differences in the magnitude of responses between cell
lines, the results follow the same general trend in all cell lines, suggesting that there is not
a major difference in response between the two types of cancer cells (i.e. carcinoma v.
sarcoma). This suggests the possibility that the interactions between platelets and cancer
cells in dogs are fundamentally different from those interactions in humans and mice.
In conclusion, releasate from canine platelets activated by collagen has an
opposing effect on cancer cell migration to that induced by releasates derived of thrombin
or ADP activation. This observation suggests indicates that canine platelets may be
selectively activated. Our findings also suggest that the interaction between canine
platelets and evaluated cancer cell lines might involve platelet activation through
engagement of thrombin and/or ADP receptors.
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CHAPTER VI
CANINE PLATELETS DOWNREGULATE EPITHELIAL TO MESENCHYMAL
TRANSITION-RELATED TRANSCRIPTION FACTORS IN CANCER CELLS

Part of the content of this chapter was accepted for publication: Bulla SC, Badial
PR, Silva RC, Lunsford K, Bulla C. (in press). Canine platelets inhibit osteosarcoma cell
migration. Journal of Comparative Pathology.
6.1

Introduction
Platelets have consistently been demonstrated to promote tumor cell survival and

increase metastatic cell seeding in mice (Labelle et al., 2011, 2014; Schumacher et al.,
2013). Additionally, induced thrombocytopenia and antiplatelet therapy have been shown
to inhibit the development of metastases in several tumor types (Gasic et al., 1973; Gasic
et al., 1968; Labelle et al., 2011). In tumor cells of epithelial origin, migration and
metastases are mainly dependent on a well-described phenotypical change named
epithelial-to-mesenchymal transition (EMT) (Gunasinghe et al., 2012; Yao et al., 2011).
EMT confers migratory and invasive abilities to the cancer cell by a coordinated process
that involves increased expression of Snail, zinc finger E-box-binding homeobox (ZEB),
and Twist transcription factors, downregulation of the adherent junction protein Ecadherin, and upregulation of another adherent junction protein, N-cadherin (G. Yang et
al., 2013). Epithelial tumors usually express high levels of E-cadherin, whereas
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mesenchymal and mesenchymal-like cells express high levels of N-cadherin, fibronectin,
and vimentin (Kalluri & Weinberg, 2009).
In dogs, the role of platelets in cancer cell migration, metastasis, and/or change in
expression of EMT markers is largely unknown. Our research group has demonstrated
that canine platelets hinder migration of tumor cell lines, suggesting that, in dogs,
platelets might inhibit the metastatic potential of cancer, particularly in the case of
osteosarcoma (Bulla et al., in press).
The aim of the present study is to investigate whether EMT-related transcription
factors and cadherins are altered in canine cancer cells when in contact with platelets.
Our hypothesis is that platelets will decrease EMT-related changes in transcription
factors and switches expression of cadherins. To test this hypothesis, in vitro expression
of the EMT-related transcription factors Twist1, ZEB1, Snail2, and E- and N-cadherins
were evaluated in a canine osteosarcoma cell line and a mammary gland tumor cell line
after incubation with platelets from healthy dogs.
6.2
6.2.1

Material and methods
Experimental design
The cell lines used in this work were derived from spontaneous canine

osteosarcoma and mammary gland tumors. The study was done as three independent
experiments, at two different times. At the first time, the experiments one and two were
done with osteosarcoma and mammary gland tumor cells, respectively, co-incubated with
platelets. The mRNA expression of the above-mentioned EMT-related transcription
factors was then measured. Subsequently, in a third experiment, we expanded the first
study of the osteosarcoma cells by measuring the expression of cadherin mRNA, in
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addition, the same EMT-related transcription factors measured in experiments one and
two.
For cell treatments, purified intact canine platelets were added to and incubated
with tumor cell cultures for 48 hours. The cells were then collected and frozen. Total
RNA was later extracted and the expression of mRNA transcripts of the EMT-related
transcription factors and cadherins was measured by quantitative reverse transcriptasepolymerase chain reaction (qRT-PCR).
6.2.2

Cell culture
The osteosarcoma cells OSA-8 were kindly provided by Dr. Jaime Modiano,

College of Veterinary Medicine, University of Minnesota; (Scott et al., 2011) and were
maintained in Dulbecco’s Modified Eagle’s medium supplemented with 1% fetal bovine
serum (Gibco, Grand Island, NY, USA), 0.1mg.mL-1 Primocin (InvivoGen, San Diego,
CA, USA) and 1% HEPES (Sigma-Aldrich, St Louis, MO, USA). Mammary gland tumor
cells (CF34.Mg, #CRL-6228, ATCC, Manassas, VA, USA) were maintained in the same
medium, minus HEPES. The cells were seeded and split in T75 flasks up to 80-100%
confluency and kept in a 5% CO2 incubator (Thermo Scientific, Waltham, MA, USA).
6.2.3

Blood collection
Blood was collected from young female Treeing Walker Coonhound dogs. Health

statuses of these animals were routinely confirmed through physical examination and
screening blood tests (complete blood count, serum chemistry, heartworm test).
Venipunctures were performed on the jugular vein using a 20-gauge needle into a syringe
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containing 3.2% sodium citrate. Blood draws were done with minimal trauma and sample
handling was performed carefully to avoid in vitro platelet activation.
6.2.4

Platelet sample preparation
Purified platelet isolation was performed using the density centrifugation protocol

with 1.063 g/ml iodixanol density barrier (OptiPrepTM, Sigma-Aldrich®, St. Louis, MO)
described by our research group (Trichler et al., 2013). This protocol results in highly
purified platelets, and it has repeatedly been shown in our laboratory, by Annexin V
binding and flow cytometry, to not cause platelet activation, detection. Briefly, whole
blood was layered on top of the density barrier, and spun at 350 × g, for 15 minutes, at
20ºC, with no brake. After centrifugation, one milliliter of the interface cloudy layer,
which consisted of the purified platelet sample, was aspirated. In the third experiment, the
protocol was slightly modified and instead of whole blood, three milliliters of platelet
rich plasma was added on top of the barrier. This modification was implemented in our
laboratory after the first two experiments were carried out, and it was developed in order
to improve platelet yield and sample purity by reducing levels of contaminating
leukocytes and erythrocytes. This optimized protocol was used in the last experiment of
this study. Platelet concentration and leukocyte and erythrocyte numbers were assessed
by manual counts using a hemocytometer.
6.2.5

Tumor cell treatment with platelets
Before the experiments, 105 osteosarcoma cells or 2.5 x 105 mammary gland

tumor cells were seeded per well in 6-well plates (Corning, Corning, NY, USA), and
incubated at 37C for 24 hours (osteosarcoma cells) or overnight (mammary gland tumor
123

cells) to allow cells to attach to the wells. After attachment, the media was removed, and
platelets resuspended in fresh media were added to the wells. In all experiments, platelets
were co-cultured with tumor cells (n = 3-6) at a rate of 100 platelets per each tumor cell.
As control groups for each cell line, cells were incubated with media only. After 48 hours
of incubation, the supernatant was removed, and the cells were detached and frozen at
−80°C for RNA extraction.
6.2.6

Real-time quantitative reverse transcription PCR (qRT-PCR)
Total RNA was isolated using the RNeasy® Mini Kit (Qiagen, Valencia, CA). The

relative purity and quality of the isolated RNA were analyzed using the NanoDrop® 1000
Spectrophotometer (Thermo ScientificTM, Waltham, MA). One-step qRT-PCR reactions
were carried out using the GoTaq® Probe 1-step qRT-PCR system (Promega, Madison,
WI) and TaqMan® Gene Expression Assays (Life TechnologiesTM, Grand Island, NY) to
amplify canine CDH1 (E-cadherin, Assay ID: Cf02624268_m1), CDH2 (N-cadherin,
Assay ID: Cf02644742_m1), SNAI2 (Assay ID: Cf02701218_u1), TWIST1 (Assay ID:
Cf02690938_gH), and ZEB1 (Assay ID: Cf02725837_m1) transcripts. A specific canine
GAPDH primer pair (0.9 µM) and labeled probe (0.25 µM) (Eurofins MWG Operon,
Huntsville, AL, USA) were used as a housekeeping gene (Figueiredo et al., 2013). All
reactions were done in triplicate in a total of 20 µl each, containing 10 µl GoTaq® Probe
qPCR master mix (Promega, Madison, WI), 0.4 µl of GoScript™ reverse transcriptase
(Promega, Madison, WI), 0.9 µM of each forward and reverse primer, 0.25 µM of each
probe, 5 µl of total RNA, and nuclease-free water (q.s.p). In addition, ‘‘no template’’
controls were included. Thermocycling conditions were as follows: reverse transcription
was done at 45C for 15 min, reverse transcriptase inactivation and polymerase activation
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was done at 95C for 2 min, followed by 40 cycles of denaturation at 95C for 15 sec and
annealing/extension at 60C for 1 min in a 7500 Fast Real-Time PCR thermocycler
(Applied Biosystems, Grand Island, NY, USA) according to the manufacturer’s
instructions. Relative quantification was performed using the comparative Ct method
(Livak & Schmittgen, 2001).
6.2.7

Data analysis
Statistical analysis was performed using SAS version 9.2 (SAS Institute Inc, Cary,

NC, USA), following procedures published elsewhere (Yuan et al., 2006). Briefly,
Student’s t-test was used to compare the mean Ct differences between target and
reference genes (i.e., ΔΔCt) between treatments. All comparisons were performed at the
level of P ≤ 0.05. Results are reported as fold change in mRNA expression of the platelettreated groups relative to the respective controls.
6.3

Results
In the first two experiments, exposure of both canine mammary gland tumor and

osteosarcoma cells to platelets resulted in a significantly reduced expression of TWIST1
(mammary 0.36, 95% CI [0.33, 0.39], P < 0.0001; osteosarcoma 0.66, 95% CI [0.57,
0.75], P = 0.012) and ZEB1 (mammary 0.82, 95% CI [0.72, 0.91], P = 0.021;
osteosarcoma 0.88, 95% CI [0.75, 1], P = 0.026). In both cell lines, SNAI2 expression
was also reduced but not significantly (mammary 0.89, 95% CI [0.78, 1], P = 0.065;
osteosarcoma 0.85, 95% CI [0.77, 0.93P = 0.155) (Fig 6.1 and 6.2).
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Figure 6.1

Expression of EMT-related transcription factors in canine mammary gland
tumor cells treated with platelets.

Relative fold change in mRNA expression of TWIST1, ZEB1, and SNAI2 genes in
mammary gland tumor cells (n = 3) co-incubated with or without purified platelets for 48
hours. Values were normalized against canine GAPDH reference gene. Bars represent
average fold change in mRNA expression of the platelet-treated groups compared to the
controls with standard deviations. *P < 0.0001 **P = 0.021.

Figure 6.2

Expression of EMT-related transcription factors in canine osteosarcoma
cells treated with platelets.

Relative fold change in mRNA expression of TWIST1, ZEB1, and SNAI2 genes in canine
osteosarcoma cells (n = 3) co-incubated with or without purified platelets for 48 hours.
Values were normalized against canine GAPDH reference gene. Bars represent average
fold change in mRNA expression of the platelet-treated groups compared to the controls
with standard deviations. *P = 0.012 **P = 0.026.
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Similarly, when we repeated the experiment with osteosarcoma cells, platelets
significantly downregulated transcriptional levels of TWIST1 (0.68, 95% CI [0.59, 0.78],
P = 0.004). In contrast to the previous experiment, however, SNAI2 was also significantly
downregulated (0.73, 95% CI [0.63, 0.85], P = 0.02). Also, while ZEB1 transcriptional
levels were also decreased, the decrease was not statistically significant (0.93, 95% CI
[0.79, 1.09], P = 0.56) (Fig. 6.3). Although exposure to platelets also appeared to
downregulate E-cadherin mRNA (CDH1) transcriptional levels in osteosarcoma cells,
this decrease was not statistically significant (0.78, 95% CI [0.59, 1.02], P = 0.06).
Expression of N-cadherin mRNA (CDH2) was not affected by platelet treatment (1.01,
95% CI [0.87, 1.16], P = 0.95).

Figure 6.3

Expression of EMT-related transcription factors and cadherins in canine
osteosarcoma cells treated with platelets.

Relative fold change in mRNA expression of TWIST1, ZEB1, SNAI2, CDH1, and CDH2
genes in canine osteosarcoma cells (n = 6) cells co-incubated with or without purified
platelets for 48 hours. Values were normalized against canine GAPDH reference gene.
Bars represent average fold change in mRNA expression of the platelet-treated groups
compared to the controls with standard errors.*P = 0.004. **P = 0.02.
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6.4

Discussion
The results presented here suggest that canine platelets downregulate EMT-

related transcription factors in canine cancer cell lines. Despite the differences in SNAI2
and ZEB1 expression responses between the two osteosarcoma experiments, platelets
consistently decreased TWIST1 both times in osteosarcoma and mammary gland tumor
cells. SNAI2 mRNA expression was also decreased, although not statistically
significantly in both cell lines in the first two experiments.
In our experience, the platelet purification method used in experiment three
usually yields a lower amount of leukocyte contamination when compared to the protocol
used in experiments one and two (data not shown). Therefore, it is possible that the
varied degree of leukocyte contamination between experiments contributed to differences
observed in results, However, according to our previous studies of tumor cell migration
(Chapter Four), a high number of leukocytes added to platelet samples does not appear to
interfere with the effect that purified platelets had on these cells. Thus, it is unlikely that
the low numbers of leukocytes present in both types of purified samples used in our
studies impacted the results of the experiments. Most likely, the differences observed
between the two osteosarcoma experiments were due to variability in cell or platelet
samples between the two iterations of this experiment.
The inhibition of EMT transcription factors demonstrated in this study is
consistent results from our previous studies on tumor cell migration, in which platelets
were shown to inhibit migration of canine mesenchymal and epithelial cancer cell lines
(Chapter Four). As with our previous experiments, our results here are also in
contradiction to what has been found in mouse studies, which have demonstrated that
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platelets promote tumor cell survival and increase metastatic cell seeding (Labelle et al.,
2011, 2014; Schumacher et al., 2013). Murine platelets have also been demonstrated to
upregulate Snail1, Snail2, Twist1, ZEB1, and ZEB2 transcription factors, downregulate
E-cadherin and upregulate vimentin in tumor cells (Labelle et al., 2011).
Metastasis is triggered by a multitude of tumor-host cell interactions and complex
signaling pathways in cancer cells. These interactions drive cell motility, invasion, and
dissemination out of the primary tumor microenvironment, which are mandatory steps for
the success of metastatic spread (Niinaka et al., 2010; G. Yang et al., 2013). Epithelial to
mesenchymal transition is a phenotype change that cells undergo to acquire a
mesenchymal-like characteristic, which allows them to move while maintaining loose
cell-cell contacts (Thiery, 2002; Thiery et al., 2009). This phenotype switch is well
studied in cancer cells of epithelial origin, in which this change involves a coordinated
process involving downregulation of the adherent junction protein E-cadherin and
upregulation of N-cadherin (G. Yang et al., 2013). The decrease in E-cadherin and
upregulation of N-cadherin in epithelial tumors suggests that N-cadherin expression
confers mobility to these cells. This cadherin switch is accompanied by activation of
signaling pathways upregulating and activating Snail1, Snail2, Twist1, Twist2, ZEB1,
and ZEB2 transcription factors (Gonzalez & Medici, 2014; Thiery et al., 2009). Thus, it
is reasonable to conclude that these transcription factors play important roles in cancer
progression. In fact, as an example of this importance, Snail2 has been shown to be
necessary for proliferation and invasiveness of prostate carcinoma cells. Its knockdown
inhibited invasion, decreasing cell proliferation and disturbing microtubular and actin
cytoskeletons (Baygi et al., 2010).
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Measurement of expression of these transcription factors has been shown to have
potential as a biomarker for prognosis. For instance, upregulation of Twist1 has been
associated with a poor prognosis in a variety of human cancers, and Twist1 has also been
suggested as an interesting therapeutic target (Puisieux et al., 2006).
While in epithelial cancers, a switch in expression of EMT and related
transcription factor and cadherin are better known and have a reasonably straightforward
relationship with cancer development and malignancy, in mesenchymal-origin cancers
this process is still not completely understood. Although mechanisms triggering cadherin
change in expression also occurs and is correlated with the metastatic potential of
mesenchymal cancers (G. Yang et al., 2013; Yin et al., 2012), the association between
transcription factor and cadherin expression and malignancy is not clear to date, and there
are conflicting results published in different studies.
Several studies suggested the existence of an EMT-like process in osteosarcoma
cells where, as in epithelial cells EMT, there is downregulation of E-cadherin and
upregulation of transcription factors and N-cadherin. For example, functional studies
have shown that the Snail transcription factors are required for cell motility, tumor
development, and tissue invasion in human and canine osteosarcoma cells (Sharili et al.,
2011; Sharili et al., 2013; H. Yang et al., 2011). Similarly, downregulation of Snail1,
Twist2, and N-cadherin and upregulation of E-cadherin suppresses motility, invasion,
tumor formation, and metastasis of murine osteosarcoma cells, indicating that these
transcription factors and N-cadherin participate in increasing malignancy (Niinaka et al.,
2010). Finally, significantly higher mRNA transcription and protein expression of ZEB1
has been detected in osteosarcoma tissues and in lung metastasis than is found in normal
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bone and lung tissues, confirming that ZEB1 overexpression in osteosarcoma is related to
carcinogenesis (Shen et al., 2012).
In contrast to these previous studies, other studies suggest different roles for these
transcription factors and cadherins in osteosarcoma malignancy. Twist2 and N-cadherin
overexpression, which would be related to induction of EMT in epithelial cancers, in fact,
have been shown to, attenuate murine osteosarcoma invasiveness and pulmonary
metastatic burden in mice (Ishikawa et al., 2013; Kashima et al., 2003). Moreover, it has
been suggested that E-cadherin and other cadherins function as tumor suppressor genes,
decreasing osteosarcoma migration and metastasis. Highly metastatic human and murine
osteosarcomas have been shown to express low transcriptional and post-transcriptional
levels of E-cadherin, N-cadherin, P-cadherin, and cadherin-11 (Kashima et al., 1999).
In the present study, the platelet-induced decrease in EMT-related transcription
factors in osteosarcoma was accompanied by a non-significant (P = 0.06) decrease in
expression of E-cadherin. However, the observed 95% confidence interval of E-cadherin
expression after the platelet treatment was between 0.59 and 1.02, which suggests a low
to moderate decrease in expression of such transcript. Therefore, if there were an
increased power for this comparison associated with a slightly greater treatment effect
with decreased variability among samples, or with a slightly increased number of
samples, statistical significance would likely have been achieved. Interestingly, there was
no change in N-cadherin expression in the osteosarcoma cell after platelet treatment.
Downregulation of the EMT-related transcription factors is expected to induce Ecadherin and inhibit N-cadherin expression in epithelial cells. However, our results
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suggest that in the cell line tested, the change in expression of these transcription factors
might have a different outcome effect on cadherins expression.
In conclusion, our study has demonstrated that platelets downregulate EMTrelated transcription factors in two canine cancer cell lines, and they tend to E-cadherin
expression in osteosarcoma cells. Our results suggest that platelets may play an important
role regulating the EMT process in canine cancer progression, but that this role is not
necessarily the same as noted in mice and humans.
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CHAPTER VII
DISCUSSION AND CONCLUSIONS

7.1

Final remarks
In humans, the crosstalk between cancer cells and platelets has been the subject of

research studies for many years, both in vitro and in vivo, and the role of platelets in the
growth and spread of cancer has also been intensely researched in laboratory animals.
Understanding of this interaction has great potential for the discovery of mechanisms of
cancer growth, biomarkers, and therapeutic candidates.
In veterinary medicine, apart from the use of laboratory mouse models, the
interaction between cancer cells and platelets has essentially been unexplored.
Development of this new niche of cancer research would obviously greatly benefit
oncology in veterinary medicine. Additionally, since dogs exhibit cancer biology features
that are very similar to humans, these animals can become promising candidates as a
research model. Thus, one objective of this dissertation was to evaluate the interaction
between dog platelets and cancer cells, as a preliminary step for better understanding the
dog as a cancer model. The main hypothesis was that canine platelets were similar to
human and murine platelets, and would interact similarly with cancer cells, resulting in
changes in the behavior of these cells. The results presented in this study partly support
this hypothesis, in that canine cancer cells appear to activate canine platelets, and also
canine platelets appear to alter the behavior of canine cancer cells. Interestingly,
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however, the direction of the effects of canine platelets on canine cancer cells appears to
be the opposite of the observed in human and mouse studies.
In the beginning of this study, in an effort to understand if canine platelets are
physiologically similar to those of humans and rats, we demonstrated that they contain
different alpha-granule subtypes. Unfortunately, due to difficulties in our immunostaining
technique and limitations of the imaging system utilized, we were able to demonstrate a
lack of colocalization with just one pair of adhesive proteins. One pertinent subsequent
investigation would be to attempt to detect of other proteins within canine platelet alpha
granules. Evaluation of selective release of multiple proteins using immunofluorescence
techniques would also be worth pursuing. Such developments would add a great deal of
information on how these proteins are distributed within canine platelet alpha granules,
and contribute to the understanding of the mechanism of granule release in this species.
However, before such studies on platelet subcellular protein localization can be carried
out, an imaging system with better resolution needs to be available.
A major component of this dissertation was the demonstration of impairment of
cancer cell migration by canine platelets. For this, we employed a transwell-based
migration assay, which is a widely used and accepted in vitro technique to study the
movement of cancer cells (Bersini et al., 2014; Katt et al., 2016). Unfortunately, as with
most in vitro assays, these techniques are much less complex than the true physiological
environment, and they do not encompass many factors that cells would encounter in vivo.
In order to try to overcome some of this limitation, further investigations of platelet
effects on cancer cell migratory behavior should include other migration and extracellular
matrix invasion assays. Some of these assays, such as the spheroid migration assays,
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vertical gel invasion assays, and spheroid gel invasion assays are more labor intensive but
are also considered of greater physiological relevance (Kramer et al., 2013).
The mechanisms of cancer cell-platelet interaction are largely unexplored to date,
and the molecules and signaling pathways involved in this interaction most likely vary
widely among cancer cell types. However, several molecules have already been shown to
participate in the adhesion of platelets onto cancer cells, including thrombospondin,
glycoprotein IIb-IIIa, fibronectin, von Willebrand factor, and glycoprotein Ib, as
discussed in Chapter Three. Moreover, platelet membrane components and transforming
growth factor β signaling have been demonstrated to participate in the promotion of
migration and metastasis of mouse cancer cells (Labelle et al. (2011). In our experiments,
we observed that an adenosine diphosphate receptor (P2Y12) is likely involved in the
activation of platelets by cancer cells. Therefore, blockage of other specific agonist
receptors and adhesion proteins might provide fundamental information on how this
interaction occurs. Another promising approach to assessing the importance of specific
platelet molecules on the crosstalk with cancer cells would be to employ platelets isolated
from dogs with specific inherited intrinsic and extrinsic platelet function deficiencies,
which would serve as “knockout” platelets for specific molecules. For instance, platelets
from dogs with severe forms of the most common inherited canine bleeding disorder, von
Willebrand disease, are devoid of the adhesive protein von Willebrand’s factor and have
long been used as models for research (Read et al., 1978). A more recently discovered
example is P2Y12 deficient dogs, which are mutant for this receptor and thus platelets
from affected animals have absent or nonfunctional ADP signaling (Boudreaux & Martin,
2011). Additionally, exploring how platelets derived from dogs with alpha-granule
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deficiency (gray platelet syndrome) interact with cancer cells would greatly contribute to
our understanding of platelet-cancer cell crosstalk in dogs.
In the last chapter of this dissertation, we showed that canine platelets
downregulate EMT-related transcription factors in canine cancer cell lines. A drawback
of this study was that GAPDH was used as the only housekeeping gene, and this gene
might not be the most suitable gene to be used as an internal expression control in studies
of malignancy potential in cancer cell lines. No single housekeeping gene will have stable
expression levels under all experimental conditions, particularly in cancer cells, which
can be highly heterogeneous and distinct from their normal tissue counterparts. Indeed,
GAPDH has been described by some researchers as not appropriate to be used as an
internal expression control in human breast cancer cells (Revillion et al., 2000), although
other authors have determined it to be suitable as a housekeeping gene in several cancer
cell types (Janssens et al., 2004). Furthermore, GAPDH has been used as a control in
studies with the same canine osteosarcoma cancer cell line we used (Fossey et al., 2009),
and it was chosen as a control to evaluate the effect of platelets in a mouse mammary
carcinoma cell line (Labelle et al., 2011). Therefore, due to the uncertain suitability of
GAPDH as an internal control in cancer cells, subsequent gene expression studies should
ideally include two or more housekeeping genes as internal controls, thereby allowing for
determination of which gene is most suited for further experimentation. These
experiments are in progress.
Significant advances towards understanding phenotypic changes on cells after
platelet treatment could be achieved by protein expression methods. Potential targets for
preliminary investigations could include classical markers for EMT and malignant
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potential, such as cadherins (N- and E-) and intermediate filaments (vimentin and
cytokeratin). Also, large-scale approaches such as proteomics would facilitate a more
comprehensive evaluation of the effect of platelets on protein expression by cancer cells.
In the studies described in this dissertation, five different canine cancer cell lines
were used. Three of those were isolated from osteosarcoma in dogs, one was derived
from a mammary carcinoma, and another was an uncharacterized mammary gland tumor.
Certainly, canine osteosarcomas are known to be invariably highly malignant and
metastatic. However, our other two cell lines lack phenotypic and behavioral
characterization. Recently, our research group performed pilot immunolabeling studies
with several of these cell lines, to determine the presence of vimentin and cytokeratin,
which are mesenchymal and epithelial markers, respectively. The osteosarcoma cell line
tested was highly positive for vimentin and negative for cytokeratin, as expected.
However, surprisingly, the mammary carcinoma cell line was also highly positive for
vimentin and only weakly positive for cytokeratin, which was the opposite of the
expected result for epithelial-origin cells. These are preliminary results and are not
enough to definitely characterize the mammary cell line as mesenchymal. However, this
information has prompted us to wonder whether the type of effect that platelets have on
cancer cell migration is dependent on specific characteristics of the cell, for example, the
amount of vimentin and cytokeratin expressed. Thus, it is paramount that the effect of
platelets is evaluated on cytokeratin-positive canine cancer cells, that is, typical
carcinomas.
Lastly, it is important to note that, the biological relevance of the treatment effects
obtained in these studies is still unknown, regardless of the results of statistical analysis.
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Defining when an effect is biologically important or relevant is not a statistical decision,
but a subjective one. This decision is related to effect size, power, and sample size. The
choice of an appropriate effect size requires an appreciation of the biological material and
context being investigated and is ultimately dependent on the researcher experience and
specific knowledge (Lovell, 2013). Therefore, in order to better determine the biological
relevance of the data, the effect size and nature that will be considered relevant should be
defined before experiments take place, so experiments can be designed to have sufficient
statistical power (Martin et al., 2009). In the case of this research, too little is currently
known regarding how much of change in the variables analyzed is associated with
biological relevance. The results presented here are nonetheless crucial as first steps in
this area of veterinary cancer research since these studies suggest directions that should
be pursued in further investigations.
7.2

Conclusions
In summary, the work presented here shows that canine platelets have important

similarities to human and mice, including selective protein packaging, the presence of an
effect on cancer migration, and activation of platelets by cancer cells. Critical differences,
however, might also exist, since canine platelets seem too likely inhibit cancer cell
migration, instead of promoting migration as is reported in human and mice studies.
Since our experiments were performed with cells with a different phenotype than the
majority of studies published previously, we do not know at this moment if this
difference is due to the different species or due to different cancer cell types. Therefore,
to determine the reason for this difference, it is imperative that more canine cancer cells
are tested, especially carcinomas.
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Regardless of whether the difference observed in our studies is due to our cell
lines or due to the animal species, the fact that canine platelets might be able to inhibit
cancer cell migration and metastasis permits us to explore this newfound property.
Determining the molecules and mechanisms responsible for this inhibition will help
identify potential therapeutic targets, either by enhancement of specific platelet functions
or by ex vivo manipulation of platelets to be used in therapy.
Finally, a major question that arises from this study is the role of platelets in dogs
with osteosarcoma. Since platelets repeatedly inhibited migration of osteosarcoma cell
lines, the clinical implications of this interaction should be further explored. An important
question to be answered next is whether platelet number and function are related to
disease outcome in osteosarcoma patients. Understanding how platelets affect cancer
progression may allow for improvements in prognostic and treatment plans.
In conclusion, the results of this study have revealed important interactions
between canine cancer cell lines and platelets in vitro. Our findings suggest that platelets
most likely have a significant role in cancer growth in dogs and that cancer cells most
likely affect platelet function in cancer patients.
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